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ABSTRACT 
Several hundred million people throughout the world have the metabolic syndrome, a cluster of 
metabolic and cardiovascular disorders. Obesity is one of the main underlying risk factors for 
the metabolic syndrome. The increasing prevalence of obesity and the metabolic syndrome is 
alarming because they increase the risk of type 2 diabetes, coronary heart disease, 
cardiovascular disease and premature mortality. Increasing longevity prolongs exposure to 
metabolic and cardiovascular risk factors. Even so, older persons, especially women, have been 
underrepresented in epidemiological studies. The purpose of the present thesis is to expand 
knowledge on the predictors and consequences of the metabolic syndrome in aging men and 
women. The thesis is based on two population studies. The association of cardiorespiratory 
fitness with the metabolic syndrome was evaluated in a large cohort of men and women, 57 to 
79 years of age. The associations of the metabolic syndrome and body adiposity with the 
progression of preclinical carotid atherosclerosis, and the associations of low-grade 
inflammation with the metabolic syndrome were evaluated in a 12-year follow-up study of 
elderly women, 70 to 80 years of age at the end of the follow-up. 
 Cardiorespiratory fitness had a strong, inverse, graded and independent association with the 
metabolic syndrome in older men and women. Those in the lowest third of directly measured 
maximal oxygen uptake (VO2max) had a 10 times higher risk of having the metabolic syndrome 
than those in the highest third of VO2max. Even a slight increment in high-sensitivity C-reactive 
protein (hsCRP) concentration in elderly women was associated with a 4 to 6 times higher risk 
of developing the metabolic syndrome than in those whose hsCRP concentration decreased 
during 12 years. The progression of carotid intima-media thickness (IMT) during 12 years was 
greatest in women with both a larger waist circumference and a smaller hip circumference. The 
mean increase in the carotid IMT was 2 times greater in women who developed the metabolic 
syndrome than in women who did not. 
Cardiorespiratory fitness and hsCRP may be valuable additions to the definition of the 
metabolic syndrome. Identification of the metabolic syndrome may improve the prediction of 
preclinical atherosclerosis. When used in conjunction with other metabolic and cardiovascular 
risk factors, low cardiorespiratory fitness and elevated hsCRP may have additive predictive 
power in identifying individuals with multiple, often only mildly elevated cardiovascular risk 
factors, who are at increased risk of developing chronic and progressive diseases and who may 
benefit from lifestyle therapy targeting exercise and weight management. These findings 
emphasize the importance of ongoing efforts to identify and control the metabolic syndrome as 
early as possible to prevent atherosclerotic disease, also in the older population. 
National Library of Medicine Classification: WB 286, WD 210, WG 550, WG 595.C2, WK 820 
Medical Subject Headings: Aged; Aging; Atherosclerosis; Body Fat Distribution; Body Mass 
Index; Carotid Arteries; Carotid Artery Diseases; C-Reactive Protein; Disease Progression; 
Exercise test; Female; Follow-Up Studies; Humans; Inflammation; Insulin Resistance; Men; 
Metabolic Syndrome X; Obesity; Physical Fitness; Risk Factors; Waist-Hip Ratio 
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1. INTRODUCTION
 
The metabolic syndrome, a cluster of metabolic and cardiovascular disorders, is typically 
characterized by abdominal obesity, insulin resistance, hyperglycemia, atherogenic 
dyslipidemia and hypertension (Figure 1). Several hundred million people throughout the 
world have the metabolic syndrome (1). In most European countries and in the United 
States the prevalence of the metabolic syndrome is up to one third of the adult population 
(2-6) and the prevalence is even higher in the elderly (2,6). Increasing longevity, 
overweight and obesity prolong exposure to metabolic and cardiovascular risk factors 
which increases the number of people who have the metabolic syndrome and its 
consequences, type 2 diabetes and cardiovascular diseases (CVD). The prevalence of 
these chronic diseases is still expected to increase, because the proportion of individuals 
above 65 years of age will almost double globally within the next years (7,8). Even so, 
older persons, especially women, have been underrepresented in epidemiological studies. 
Sedentary lifestyle, unhealthy diet, genes and many other risk factors interact in the 
etiology of metabolic syndrome (Figure 1) (1,9,10). An abundant food supply and 
prepackaged fast-food with high caloric density together with every-day technologies that 
reduce the amount of physical activity have promoted the epidemic of obesity and the 
metabolic syndrome over the past several decades. Obesity, especially abdominal obesity, 
is frequently considered as the main underlying risk factor for the metabolic syndrome, 
accompanied with varying degrees and numbers of other risk factors (10). In early 2000, 
roughly half of the Finnish adult population was overweight and one fourth was obese 
(11). These prevalences are expected to increase in the future. The same trend has also 
been seen in other European countries (12) and in the United States (13). The increasing 
prevalence of obesity and the metabolic syndrome is alarming because they increase the 
risk of type 2 diabetes (5,14), coronary heart disease (CHD), CVD and premature 
mortality (15). Nearly 200 million people worldwide have diabetes and the prevalence is 
estimated to double by 2030 (16). Most cases will be type 2 diabetes. The rapid increase in 
prevalence is estimated to happen as a consequence of population aging and urbanization 
even if the prevalence of obesity remains stable (16,17).
16
Limited data are available, particularly in the elderly, on the associations of the 
metabolic syndrome with novel, non-traditional risk factors such as low-grade
inflammation and low cardiorespiratory fitness and preclinical atherosclerosis. So far, 
these risk factors for CVD have not been included in any of the definitions of the 
metabolic syndrome, due to limited evidence and for practical reasons.
The purpose of the present thesis is to expand knowledge on the predictors and 
consequences of the metabolic syndrome in aging men and women. The thesis is based on 
two population studies. The association of cardiorespiratory fitness with metabolic 
syndrome and impaired glucose homeostasis was evaluated in a large cohort of older men 
and women. The associations of the metabolic syndrome and body adiposity with change 
in carotid intima-media thickness (IMT), a noninvasive marker of preclinical carotid 
atherosclerosis, and the associations of systemic low-grade inflammation with the 
metabolic syndrome was evaluated in a 12-year follow-up study of elderly women. 
Figure 1. Predictors, components and consequences of the metabolic syndrome. The question 
mark refers to unknown risk factors. The upper boxes refer to modifiable (left box) and 
unmodifiable (right box) environmental and genetic factors that contribute to the metabolic 
syndrome. 
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2. REVIEW OF LITTERATURE 
 
2.1 Metabolic syndrome
2.1.1 Definitions of the metabolic syndrome
In recent years, several working definitions have been developed for the metabolic 
syndrome. Most international expert groups agree that the syndrome is characterized by 
abdominal obesity, dyslipidemia, elevated blood pressure, glucose intolerance and insulin 
resistance (18-21).
To provide a tool for clinicians and researchers, the World Health Organization 
(WHO) introduced a definition for the metabolic syndrome in 1998 (22), and revised it in 
1999 (18). The European Group for the Study of Insulin Resistance (EGIR) formulated 
their definition in 1999 (19), the National Cholesterol Education Program’s Adult 
Treatment Panel III (NCEP) in 2001 (20), modified by an American Heart 
Association/National Heart, Lung and Blood Institute Scientific Statement in 2005 (23), 
and the International Diabetes Federation (IDF) in 2005 (21). The mostly used definitions, 
given by WHO and NCEP expert groups, and the latest one, IDF, are given in Table 1. 
Table 1. Definitions of the metabolic syndrome 
WHO 1999 NCEP 2001 IDF 2005 
Diabetes, IFG, IGT or  
insulin resistance 
Plus 2  of the following: 3 of the following: 
Waist circumference 80 cm in 
women, 94 cm in men 
Plus any 2 of the following: 
Central obesity (WHR >0.85
in women, >0.9 in men)  
and/or BMI >30 
Waist circumference  
>88 cm in women,  
>102 cm in men
Elevated blood pressure
(140/90 mm Hg) 
Elevated blood pressure
(130/85 mm Hg and/or 
drug treatment) 
Elevated blood pressure
(130/85 mm Hg  and/or
drug treatment) 
Elevated triglycerides  
(1.7 mmol/l) 
Elevated triglycerides (1.7
mmol/l or specific treatment) 
Elevated triglycerides  
(1.7 mmol/l) and/or 
low HDL cholesterol
(<1.0 mmol/l  in women,  
 <0.9 mmol/l in men) 
Low HDL cholesterol  
(<1.29 mmol/l in women, 
 <1.03 mmol/l in men) 
Low HDL cholesterol (<1.29 
mmol/l in women, <1.03 mmol/l 
in men or specific treatment) 
Microalbuminuria (albumin 
excretion 20 µg/min or albumin 
/creatinine ratio 30 mg/g) 
Impaired fasting glycemia 
(6.1 mmol/l) 
Impaired fasting glycemia  
(5.6 mmol/l) or diagnosed 
type 2 diabetes
WHO=World Health Organization (18), NCEP=National Cholesterol Education Program (20), 
IDF=International Diabetes Federation (21), BMI=body mass index, WHR=waist-to-hip ratio, 
IFG=impaired fasting glucose, IGT=impaired glucose tolerance. 
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2.1.2 Epidemiology of the metabolic syndrome  
In majority of the 21 prospective cohort studies from Europe and the United States 
included in a recent meta-analysis, the prevalence of the metabolic syndrome according to 
NCEP or WHO criteria ranged from 23% to 46% among the general populations of 
countries with different levels of cardiovascular risk factors (15). The rates are 
comparable to those reported recently in 45-64 years old Finnish men and women (6). In a 
large study in United State citizens, the prevalence of the metabolic syndrome increased 
steeply since the age of 30 years in men and women, the increase continued until the age 
of 60 years in men and until 70 years in women and started to decline thereafter (24). The 
growing prevalence of the metabolic syndrome worldwide is undoubtedly a consequence 
of the global epidemic of obesity (12,13). The metabolic syndrome is an important risk 
factor for type 2 diabetes (14,15), which represents a steadily growing threat to human 
health in the 21st century (16). Insulin resistance contributes to impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT). About 75% of those with combined IFG and 
IGT have metabolic syndrome (25). Because type 2 diabetes has a high morbidity and 
mortality the metabolic syndrome is a serious and growing public health problem (17). A 
meta-analysis indicated that individuals with the metabolic syndrome have a 61% 
increased risk of CVD compared to those without the syndrome (15). The metabolic 
syndrome might be even a stronger risk factor for CVD in women than in men (15,26). 
Individuals with the metabolic syndrome have also increased risk of coronary hearth 
disease, myocardial infarction, stroke and mortality (15,27). In a prospective study, 
women with metabolic syndrome, even without diabetes, had at least a 2-fold increased 
risk of ischemic stroke or transient ischemic attack (28). 
2.2 Features of the metabolic syndrome 
2.2.1 Overall and abdominal adiposity 
Body composition can be indirectly estimated by body height and weight, body mass 
index as well as waist and hip circumferences, which are non-invasive, easy and 
inexpensive methods. Overweight and obesity have most often been defined by body 
mass index, calculated as the weight in kilograms divided by the square of the height in 
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meters. According to the WHO (29), overweight is defined as body mass index 25-29.9 
and obesity as body mass index 30.
Waist-to-hip ratio, calculated as the ratio of the waist circumference to the hip 
circumference, was previously acknowledged as the clinically accepted method of 
identifying patients with excess abdominal fat accumulation. However, recently waist 
circumference has been suggested as being a more practical measure of intra-abdominal 
fat mass, replacing body mass index and waist-to-hip ratio as a simpler indicator of 
visceral adipose tissue and successful weight management as well as for the assessment 
of cardiovascular risk (30,31). Because populations and ethnic groups may differ in the 
level of risk associated with a particular waist circumference (32), globally applicable 
cut-off points cannot be developed. Two ‘action levels’ for waist circumference have 
been suggested, in which individuals with a waist circumference over level 1 (men 94
cm and women 80 cm) should gain no further weight, and those with a waist 
circumference over level 2 (men 102 cm and women 88 cm) should reduce weight 
(31). For most definitions of the metabolic syndrome, waist circumference is included 
as a categorical variable indicating low risk or high risk (19-21).  
Computed tomography (33) and magnetic resonance imaging (34) can be considered 
“golden standards” for the evaluation of abdominal adiposity. Because these techniques 
are laborious and expensive, and in addition computed tomography induces radiation 
exposure, their use in large epidemiological studies is usually not feasible. Waist 
circumference is associated with intra-abdominal fat measured by computed 
tomography (35) and with total adiposity measured by magnetic resonance imaging 
(34). Moreover, waist circumference correlates with abdominal obesity better than the 
waist-to-hip ratio (30).  
Adipose tissue is a metabolically active endocrine organ in addition to its function in 
the storage of surplus energy (36). In the normal state, there is balance between adipose 
tissue lipolysis and triglyceride synthesis regulated by nutrients, hormones and 
autonomic nervous system (37). Body fat distribution, especially visceral adipose tissue 
accumulation, has harmful metabolic and medical consequences (38,39). Visceral fat is 
more resistant to the metabolic effects of insulin than peripheral fat, and the rate of 
lipolysis is higher (40-42). Insulin resistance in adipose tissue leads to an inability to 
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suppress release of fatty acids from adipose tissue and decrease in lipoprotein lipase 
activity induces decrease in clearance of triglyceride-rich lipoproteins (38). With an 
increase in visceral adipose tissue, a higher rate of flux of adipose tissue-derived free 
fatty acids to the liver may occur, which promotes an increased secretion of triglyceride-
rich lipoproteins and glucose from the liver (1,39). An increase in abdominal 
subcutaneous fat increase release of lipolytic products into the systemic circulation and 
avoid more direct effect on hepatic metabolism (1).  
Adipose tissue also contributes to systemic inflammation. Hyperplasia and 
hypertrophy of adipocytes as seen in obesity lead to an increased production of several 
adipokines such as tumor necrosis factor alpha (TNF-Į), interleukin-6 (IL-6), 
plasminogen activator inhibitor-1 (PAI-1) and reduced production of adiponectin (36). 
These adipokines include acute phase reactants and mediators of inflammation, 
thrombosis and insulin sensitivity (36). Visceral adipose tissue appears to be particularly 
active in the expression and secretion of adipokines. Adipokines and free fatty acids are 
involved in the regulation of insulin action in skeletal muscles and eventually induce 
insulin resistance (43).  
Prospective studies indicate that abdominal obesity predicts the development of the 
metabolic syndrome (44) and cardiovascular events (45,46). Prospective (47) and cross-
sectional (48) studies have found a direct association of body mass index, waist 
circumference or waist-to-hip ratio with carotid IMT in middle-aged individuals (Table 
2). Other studies in middle-aged or older individuals have not shown clear associations 
(49-51). According to prospective studies in elderly individuals, intra-abdominal fat 
appears to be an independent risk factor for myocardial infarction (52) and a large waist 
circumference for mortality (53). On the other hand, a narrow hip circumference seems 
to have an independent and inverse association with the risk of type 2 diabetes (54) and 
CVD morbidity and mortality (55-57). Excess intra-abdominal fat has been associated 
with a greater risk of morbidity and mortality than overall adiposity (53). Obesity was 
an independent risk factor for CHD mortality among men and also contributed to the 
risk of CHD death among women in a study of over 8000 middle-aged Finnish men and 
women followed for 15 years (58). An increase in body weight of 1 kg increased the 
risk of CHD mortality by 1% to 1.5%, starting at a body mass index of 22.  
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Aging is associated with an increase and redistribution of body fat (59) and a 
decrease in skeletal muscle mass due to sarcopenia (60). In advancing age, intra-
abdominal fat accumulates more rapidly than total fat, and that happens even in the 
absence of obesity (59). Already in pre-menopausal women, a selective accumulation of 
visceral fat as assessed by computed tomography occurs (61). Withdrawal of estrogen at 
menopause probably independently induces intra-abdominal fat accumulation (62-64).
Table 2. Epidemiological studies on the association of body adiposity with carotid intima-media 
thickness (IMT)                  
Author Study design Adiposity 
determination 
Result 
prospective
Hassinen M  
et al. 2007
(part of thesis, 
Study III) 
102 women, 
age 60-70 y,  
population-based, 12 y 
waist and hip 
circumference, 
BMI, WHR
Waist and hip were associated with 
IMT progression. Those with both 
larger waist and smaller hip had 
greatest progression. 
Reed D  
et al. 2003 (51) 
573 men and women, 
age 40-60 y,  
employees of company, 3 y 
sagittal and 
transverse 
abdominal 
diameters, BMI
Baseline BMI predicted IMT 
progression but sagittal and 
transverse diameters did not.  
Stevens J
et al. 2002 (50) 
9316 men and women, 
age 45-64 y, 
population-based, 9 y 
BMI BMI associated with IMT in cross-
sectional analysis, but not in 
longitudinal after adjusted for age. 
Lakka TA  
et al. 2001 (47) 
774 men, age 42-60 y, 
population-based, 
average 4 y 
waist
circumference, 
WHR, BMI
Abdominal obesity (WHR, waist) 
was an independent risk factor for 
IMT independent of BMI. 
cross-sectional
Czernichow S  
et al. 2005 (65) 
1014 men and women, 
mean age 59 y, 
from vitamin study 
waist and hip 
circumference, 
WHR, BMI, 
bioimpedance 
IMT was positively associated with 
BMI, fat mass, fat-free mass and 
waist circumference.  
De Michele M 
et al. 2002 (48) 
310 women, 
mean age 55 y, 
selected subjects  
waist and hip 
circumference, 
WHR, BMI
There was a graded and 
independent association between 
obesity (BMI, WHR) and IMT. 
Ebrahim S 
et al. 1999 (49) 
7735 men and women, 
age 55-77 y, 
from general practice register 
BMI There were no association between 
carotid IMT or carotid plaques and 
BMI.
BMI=body mass index, WHR=waist to hip ratio, y=years. 
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2.2.2 Insulin resistance 
Insulin resistance is believed to be a pathophysiological disturbance that underlies many 
of the components of the metabolic syndrome. The components of the metabolic 
syndrome occur more commonly in overweight or obese person, because excess 
adiposity increases the likelihood of having insulin resistance (66,67). One half to two 
thirds of the individuals with the metabolic syndrome (66,68,69) and half of overweight 
and obese persons (66) have insulin resistance whereas the prevalence of insulin 
resistance in those without metabolic syndrome is 10 to 30 per cent (68,69). There are 
individuals who are obese but otherwise metabolically normal with high levels of 
insulin sensitivity (70,71). On the other hand, insulin resistance can be present in normal 
weight individuals (72). A follow-up study of young children represents that 
hyperinsulinemia may predict weight gain and obesity (73). Both genes, age and 
lifestyle factors, like inactivity and overeating, contribute to the development of insulin 
resistance (67,74). 
An overabundance of circulating free fatty acids, derived mainly from adipose tissue 
is a link between obesity and insulin resistance (67). A free fatty acid overload and
following insulin resistance have metabolic consequences both in the liver, pancreas and 
peripheral tissues (Figure 2). In individuals with visceral adiposity, free fatty acids have 
direct access to the liver and result in increased hepatic glucose production and fasting 
hyperglycemia (74). Elevated levels of fatty acids in the peripheral circulation decrease 
the sensitivity of muscle tissue to the action of insulin (74). To counterbalance this 
insulin resistant state and maintain normal blood glucose levels, insulin secretion is 
increased resulting hyperinsulinemia (9).  When insulin-resistant muscle is already 
overloaded with lipid, some of the excess fatty acids are diverted to the liver, which 
promotes the development of fatty liver and dyslipidemia (75). The lipoprotein 
abnormalities in insulin resistance are hypertriglyceridemia, low levels of high density 
lipoprotein (HDL) cholesterol and an increased amount of small low-density lipoprotein 
(LDL) particles (76).  
The relationship between insulin and blood pressure is complex. Normally, insulin 
increases sympathetic nerve activity but dilates resistance arterioles in skeletal muscle 
(77), primarily by stimulation of nitric oxide release by endothelial cells. In insulin 
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resistance this effect is diminished (76). In addition, hyperinsulinemia may directly 
elevate blood pressure by raising renal sodium reabsorption (78). Although resistance to 
insulin-mediated glucose disposal and compensatory hyperinsulinemia are common in 
patients with hypertension, not all hypertensive patients have insulin resistance and 
hyperinsulinemia, and hypertension does not develop in all subjects with insulin 
resistance (79). Insulin resistance may contribute to hypertension through other 
mechanisms, such as vascular damage caused by chronic abnormalities in lipid and 
glucose metabolism (76,80). 
LIVER 
-Increased glucose  
 production  
-Dyslipidemia 
 (HDL Ļ,
  triglyceridesĹ,
  small dense LDL) 
-Inflammation
SKELETAL 
MUSCLES 
-Reduced effect of 
  insulin 
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 uptake
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SYSTEM 
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 dysfunction (NOĻ)
-Elevated blood  
  pressure 
-Impaired  
 thrombolysis 
                                          INSULIN RESISTANCE
PANCREAS 
-Increased insulin 
 secretion to 
 compensate  
 hyperglycemia 
-ȕ-cell exhaustion in
 response to  chronic
 hyperglycemia 
             
Figure 2. Adverse effects of insulin resistance in liver, pancreas, skeletal muscles and vascular 
system. (NO=nitric oxide) 
Insulin resistance is associated with an increased risk of type 2 diabetes (67), and 
diabetes develops in many persons with metabolic syndrome (14,81). Insulin resistance 
may have an independent effect on atherogenesis (82) and be an independent risk factor 
for atherosclerotic CVD (83,84). Aging is usually associated with increased insulin 
resistance in parallel to increased production of proinflammatory cytokines (85,86). The 
loss of muscle mass (60) and increase in body adiposity (59) associated with aging 
promote insulin resistance. In a 6-year follow-up study among 208 initially healthy 
volunteers, insulin resistance was associated with an increased risk of developing age-
related disease such as type 2 diabetes, hypertension and CVD, while these endpoints 
did not occur in the most insulin sensitive third (87).  
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2.2.3 Impaired glucose homeostasis  
Elevated fasting glucose levels are an important component of metabolic syndrome, but 
neither IFG nor diabetes is an absolute criterion. Insulin resistance is one apparent factor 
in development of IFG, IGT, and type 2 diabetes (75,88). Increased free fatty acid levels 
are associated with resistance to insulin-mediated glucose uptake and metabolism in 
muscle and an increase in glucose production and release by the liver (67,89). 
Pancreatic ȕ-cell dysfunction is a critical component in the pathogenesis of type 2 
diabetes (89). Glucose intolerance develops when insulin secretion capacity of 
pancreatic ȕ-cells declines, losing the ability to suppress hepatic glucose uptake and to 
compensate for insulin resistance in target tissue (76,89). Whereas insulin insensitivity 
is an early phenomenon partly related to obesity, in genetically susceptible individuals 
pancreatic ȕ-cell function declines gradually over time already when the glucose level is 
still within the normal range, before the onset of clinical hyperglycemia (67,89). When 
insulin resistance is combined with ȕ-cell defects in glucose-stimulated insulin 
secretion, IGT, IFG, or type 2 diabetes can result (90). 
Peripheral insulin resistance is most characteristic of IGT, whereas insulin-mediated 
failure to suppress hepatic glucose output are more prominent feature in IFG (91). IFG 
is more common in men than women in virtually all ages, but up to eight times higher in 
European men aged 50 to 70 years (91). Conversely, the prevalence of IGT is higher in 
women than men, except in Europeans over the age of 80 (91). IFG and IGT are strong 
predictors of future diabetes (92,93) and represent intermediate stages in the progression 
from metabolic syndrome to type 2 diabetes (88). The incidence of subsequent diabetes 
is highest in individuals with combined IGT and IFG (91). The risk of CVD increases 
with the progress of glucose intolerance (94)
In a population-based prospective study, IGT and type 2 diabetes were strong 
independent predictors of advanced carotid atherosclerosis (95). In a metaregression 
analysis of 20 studies with a mean follow-up of 12 years, a continuous positive 
relationship was found between initial fasting and postprandial glucose levels and CVD 
events. The relationship was found even below the current thresholds for IFG and IGT 
(96). Both hyperglycemia and diabetes were predictors of all-cause and CVD mortality 
in a prospective study of young and middle-aged adults (97). 
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2.2.4 Dyslipidemia 
Dyslipidemia among individuals with overweight or the metabolic syndrome is 
characterized by elevated triglycerides, low levels of HDL cholesterol and high level of 
small LDL cholesterol particles (98-100). Insulin resistance in fat cells leads to 
increased lipolysis with release of fatty acids (90). With an increase in free fatty acid 
flux to the liver, increased production of triglyceride-rich very low density lipoprotein 
cholesterol occurs (101,102). Triglyceride accumulation in the liver may decrease 
hepatic insulin sensitivity and contribute to dyslipidemia (100,103). Plasma LDL 
cholesterol levels are often normal in patients with the metabolic syndrome, but LDL 
particles are smaller than normal, making them more able to penetrate the endothelial 
wall and more susceptible to oxidation, a state associated with increased cardiovascular 
risk (104-106). HDL cholesterol has an established role in reverse cholesterol transport 
(107). HDL cholesterol also has anti-atherosclerotic and anti-inflammatory properties. 
Low plasma HDL cholesterol levels have been related to an increased risk of CHD and 
stroke (108-111). Middle-aged and elderly women with diabetes have a larger decrease 
in HDL cholesterol and greater decrease in LDL size than diabetic men relative to their 
nondiabetic counterparts (112).
 
2.2.5 Elevated blood pressure 
Elevated blood pressure has been suggested to be a component of the metabolic 
syndrome (18,20). However, the associations of blood pressure with other components 
of the metabolic syndrome have been weaker than the associations between other 
components of the metabolic syndrome (79,113). In several studies using factor 
analysis, blood pressure has been identified as a factor distinct from the other metabolic 
syndrome components (81,114,115). Although the association between obesity and 
hypertension is documented (116), the mechanism supporting the association between 
insulin resistance and hypertension is partly unclear (80). Acute increases in plasma 
insulin within the physiological range elevate sympathetic neural outflow but produce 
vasodilatation and do not elevate arterial pressure in normal humans (77). In addition to 
insulin’s direct action to kidney (sodium retention), insulin and increased levels of free 
fatty acids may stimulate the activity of the sympathetic nervous system causing 
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vasoconstriction, and may thus play an essential role in linking obesity and insulin 
resistance to hypertension (78).
Blood pressure, especially systolic, is associated with mortality from cardiovascular 
and other causes, and the incidence of stroke and coronary disease (117). According to a 
recent study, the contribution of metabolic syndrome components to the risk of CVD 
and all-cause mortality is mainly related to blood pressure along with glucose 
abnormalities, with no contribution of the other components (118). The result of a 
prospective study indicates that individuals with essential hypertension with high 
triglycerol and low HDL cholesterol are at greatest risk of CVD (119).
2.2.6 Poor cardiorespiratory fitness
Cardiovascular system responds to exercise with many adaptations to assure that active 
muscles blood supply is appropriate to metabolic needs, the generated heat is dissipated 
and blood supply to the brain and heart is maintained. Maximal oxygen uptake (VO2max)
is the commonly used measurement which describes the maximum volume of blood that 
the heart can pump (cardiac output) and the capacity of the lung to oxygenate the blood 
and the working muscle to use it at maximal physical exertion (120).  
Physical activity is the principal determinant of cardiorespiratory fitness although 
non-modifiable factors, like genes, gender and age have also strong influence (121,122). 
Men have 10 to 20% greater VO2max than women partly because a larger proportion of 
muscle mass and a smaller body fat content, a greater stroke volume and a higher 
hemoglobin concentration than women (123). Age-related decline in VO2max is
approximately 10% per decade between 25 and 75 years (124). Physical limitations 
resulting from sedentary lifestyle, disabling diseases, medication, loss of coordination 
and lack of familiarity of required exercise skill may limit VO2max (124). 
Cardiorespiratory fitness is associated with many components of the metabolic 
syndrome, like waist circumference, fasting glucose, insulin resistance, HDL 
cholesterol, triglyceride levels, and blood pressure (125-130). Cross-sectional studies 
have demonstrated an inverse association for cardiorespiratory fitness with the 
metabolic syndrome (131-135) or clustering of its abnormalities (125,126,130,136) 
(Table 3). Population-based studies and data from older individuals are limited. Also, 
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few prospective studies have assessed the relation of cardiorespiratory fitness to 
metabolic syndrome incidence (Table 3). In a 4-year study, middle-aged men in the 
upper third of VO2max were nearly 75% less likely than unfit men to develop the 
metabolic syndrome (137). In a 15-year study, young adults with poor fitness were 3 to 
6 times more likely to develop diabetes, hypertension and the metabolic syndrome than 
those with high fitness (127). In a 5-year study, the risk for metabolic syndrome was a 
half lower in men and women in the upper third of cardiorespiratory fitness than those 
in the lower third (138). In some studies no independent association between 
cardiorespiratory fitness and the metabolic syndrome was found (139,140). 
Low cardiorespiratory fitness is associated with an increased risk of IFG and type 2 
diabetes (141), CVD and mortality (142-145). Obese individuals with at least moderate 
cardiorespiratory fitness have lower rates of CVD or mortality than their normal-weight 
and unfit peers (144). In a prospective study of middle-aged men, even a small 
improvement in physical fitness was associated with a significantly decreased risk of 
death (143).
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Table 3. Epidemiological studies on the association of cardiorespiratory fitness (CRF) and metabolic 
syndrome (MS) 
 
Author 
 
Study design 
MS definition / 
Measure of CRF 
 
Result 
prospective
La Monte M 
et al. 2005 (138) 
9007 men 1491 women, 
mean age 44 y, selected 
subjects, 5.7 y 
NCEP/ maximal 
treadmill time 
Low CRF was a strong, 
independent predictor of MS in 
men and women.  
Ekelund U 
et al. 2005 (140) 
249 men 356 women, 
mean age 53 y, 
population-based, 5.6 y 
MS risk score/ 
submaximal test 
(heart rate) 
CRF was not an independent 
predictor of MS after adjusting 
for physical activity.  
Carnethon M 
et al. 2003 (127) 
2029 men 2458 women, 
age 18-30 y, 
population-based, 15 y 
NCEP/ maximal 
treadmill time  
Low CRF was associated with 
development of MS.  
Laaksonen D 
et al. 2002 (137) 
612 men, age 42-60 y, 
population-based, 4 y 
WHO, NCEP/ 
directly measured 
VO2max 
Men in the upper third of 
VO2max were 75% less likely to 
develop MS than unfit men. 
cross-sectional
Hassinen M  
et al. 2008 (part of 
thesis, Study I) 
671 men 676 women, 
57-79 y, 
population-based 
NCEP/ directly 
measured VO2max
Men and women with lowest 
third of VO2max had a 10 times 
higher risk of MS. 
Wijndaele K 
et al. 2007 (136) 
571 men 448 women, 
mean age 46 y, 
random community 
sample 
Continuous MS 
risk score/ 
directly measured 
VO2peak
CRF was inversely associated 
with MS risk score 
independently of muscular 
strength in men and women. 
Ekelund U 
et al. 2007 (130) 
1709 boys and girls,  
age 9-16 y, 
population-based 
MS risk score/ 
incremental cycle 
ergometer test 
CRF and physical activity were 
independently associated with 
clustered risk factors.  
Finley C 
et al. 2006 (135) 
9007 men 2826 women,  
mean age 45 y,  
selected subjects 
NCEP/ maximal 
treadmill time 
CRF was inversely associated 
with the prevalence of MS.  
Jurca R 
et al. 2004 (134) 
8570 men,  
mean age 43 y, 
selected subjects 
NCEP CRF was inversely associated 
with prevalence of MS even 
after adjusting for strength. 
Farrell S 
et al. 2004 (133) 
7104 women,  
mean age 45 y,  
selected subjects 
NCEP/ maximal 
treadmill time  
Prevalence of MS was lower 
across progressively higher 
levels of CRF. 
Franks P 
et al. 2004 (139) 
874 men and women,  
mean age 54 y, 
population-based 
MS risk score/ 
submaximal test 
(heart rate) 
CRF had borderline association 
with MS after adjustment for 
physical activity.   
Lakka TA 
et al. 2003 (132) 
1069 men,  
age 42-60 y,  
population-based 
WHO modified/ 
directly measured 
VO2max
CRF was inversely associated 
with MS.  
Kullo I 
et al. 2002 (131) 
360 men, mean age  
48 y, volunteers  
NCEP/ maximal 
treadmill time 
CRF was inversely associated 
with MS. 
Carroll S 
et al. 2000 (126) 
711 men,  
mean age 47 y, 
selected subjects 
2 MS risk scores/ 
submaximal test 
(heart rate) 
CRF was inversely associated 
with clustering of metabolic 
abnormalities. 
Whaley M 
et al. 1999 (125) 
15537 men 3899 women, 
mean age early 40s, 
selected subjects  
Deadly quartet/ 
maximal treadmill 
time  
Low CRF was associated with 
an increased clustering of 
metabolic abnormalities. 
NCEP=National Cholesterol Education Program, WHO=World Health Organization, y=years 
VO2max/VO2peak=Maximal/peak oxygen consumption.
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2.2.7 Systemic low-grade inflammation 
 
C-reactive protein (CRP) is an acute phase reactant and levels may increase up to 1000-
fold in response to major infection or trauma (146). In normal clinical practice CRP 
values below 10 mg/l are considered normal. Higher values indicate infection, 
inflammation or necrosis. Increased serum concentration of high-sensitivity CRP 
(hsCRP) is a marker of low-grade inflammation, and sensitive immunoassays are 
capable to detect also very low serum CRP concentrations (<1 mg/l). Even slightly 
elevated serum concentrations of hsCRP predict clinical manifestations of 
atherosclerotic CVD (147-149). Although serum CRP concentrations may increase in 
response to acute illness concentrations are remarkably stable over long period of time 
when measured in asymptomatic adults (146).  
CRP is primarily secreted by the liver in response to variety of inflammatory 
cytokines. Elevated plasma CRP concentrations have been reported in individuals with 
abdominal obesity, especially in the obese with large depots of visceral adipose tissue 
(150). Elevated CRP concentrations accompanying obesity may signify an increased 
concentration of adipocytokines and a proinflammatory state, which is associated also 
with insulin resistance (151). In obesity, white adipose tissue is characterized by an 
increased production and secretion of a wide range of inflammatory molecules 
including TNF-Į and IL-6. These cytokines may have local effects on adipose tissue 
physiology and also systemic effects on other organs (152). Process linked to chronic 
inflammation decrease insulin action, whereas insulin resistance leads to worsening of 
inflammation (153).  
TNF-Į is a pro-inflammatory cytokine that is produced and secreted from 
adipocytes. TNF-Į is increased in the adipose tissue and skeletal muscle of insulin 
resistant humans (154). Within adipose tissue, TNF-Į causes adipocyte insulin 
resistance (152) and impairs insulin signaling (155). Via downregulation of lipoprotein 
lipase it inhibits lipid storage in adipose tissue (155). TNF-Į has important effects on 
whole-body lipid metabolism, raising serum triglyceride levels by stimulating very low 
density lipoprotein cholesterol production (153).  
IL-6 has been classified as a cytokine with both a pro- and an anti-inflammatory 
actions (156,157). On average 30 % of circulating IL-6 in resting conditions originate 
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from adipose tissue (158). Abdominal adipose tissue release more IL-6 than 
subcutaneous adipose tissue (159). During exercise, IL-6 is produced locally in working 
skeletal muscle, and low muscle glycogen content stimulates the production (157). 
During exercise, IL-6 contributes to the maintenance of glucose homeostasis, stimulates 
adipose tissue lipolysis, and may also inhibit the effect of TNF-Į (157). On the other 
hand, it has been proposed that IL-6 alters insulin sensitivity, increases hepatic 
production of fibrinogen and CRP, is procoagulant and stimulates adhesion of 
circulating leucocytes to the vascular endothelium (156). IL-6 also stimulates the central 
and the sympathetic nervous systems and might result in hypertension contributing to 
higher concentration of angiotensin II, which is a potent vasoconstrictor (153). Data 
from population-based studies have shown that elevation of IL-6 predicts total and 
cardiovascular mortality (160,161). 
AMP-activated protein kinase (AMPK) is a major regulator of energy balance and 
glucose and lipid metabolism at both cellular and whole body levels (162). AMPK 
switches cells from an anabolic state where nutrients are taken up and stored to a 
catabolic state where they are oxidized (162). IL-6 may mediate or modify some of 
AMPK actions in muscle and adipose tissue (163). As IL-6, also AMPK is activated by 
exercise and absence of glucose (163). In a recent animal study, IL-6 knockout mice had 
decreased AMPK activity and developed components of the metabolic syndrome, such 
as obesity, dyslipidemia and glucose intolerance (163). 
Adiponectin is an anti-inflammatory cytokine produced by adipocytes that circulates 
at relatively high levels in the blood (164,165). Adiponectin activates AMPK (166), 
improves insulin sensitivity, inhibits inflammation and may have direct 
antiatherosclerotic effects (164,165). Adiponectin levels are reduced in obese 
individuals, especially in those with abdominal obesity (167). Reduced adiponectin 
levels contribute to insulin resistance, hyperglycemia and endothelial dysfunction 
(164,165). In a recent study, lower adiponectin levels were associated with most of the 
components of the metabolic syndrome and the metabolic syndrome itself (168). 
Cytokines and free fatty acids increase also the production of fibrinogen and 
coagulation factor, PAI-1, in the liver, which complements the overproduction of PAI-1 
by especially visceral adipose tissue (1). 
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Aging is associated with increased inflammatory activity (169,170). In a cohort of 
81-year old men and women, aging was associated with increased circulating levels of 
TNF- Į, and high inflammatory activity was associated with increased prevalence of 
clinical diagnosis of atherosclerosis (171). Limited data on the association of low-grade 
inflammation with the metabolic syndrome are available in the elderly (172), especially 
from long-term studies. 
Cross-sectional studies have found associations of hsCRP with metabolic syndrome 
(172-179) (Table 4) and its components, including obesity (180), insulin resistance 
(172,173,180), dyslipidemia (180), elevated blood pressure (181) and endothelial 
dysfunction (180). Prospective studies in middle-aged individuals have observed that 
increased serum hsCRP concentrations predict the development of metabolic syndrome 
and type 2 diabetes (182-184) (Table 4). 
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Table 4. Epidemiological studies on the association of high-sensitivity C-reactive protein (hsCRP) and 
metabolic syndrome (MS)     
Author Study design Definition Result 
prospective
Hassinen M 
et al. 2006
(part of thesis, 
Study II) 
103 women,  
age  60-70 y,  
population-based, 12 y 
NCEP Women with any increase in hsCRP 
during 12 years had a 4-6 times higher 
risk of MS than those whose hsCRP 
decreased. 
Laaksonen D 
et al. 2004 (184) 
680 men,  
age 42-60 y, 
population-based, 11 y 
NCEP
WHO 
Men with hsCRP 3 mg/l had over 3 
times higher risk of MS and 4 times 
higher risk of diabetes than those with 
hsCRP<1.0 mg/l. 
Ridker P 
et al. 2003 (183) 
14719 women, 
mean age 54 y, 
selected subjects, 8 y 
NCEP hsCRP concentrations were higher in 
women with MS. There was a linear 
increase in hsCRP with the increase of 
MS components. 
Han T 
et al. 2002 (182) 
1244 men and women,  
mean age 46 y,  
population-based, 6 y 
Own 
definition  
Women with hsCRP in the highest third 
had 4 times higher risk of MS. In men 
hsCRP did not predict MS.   
cross-sectional
Ukkola O 
et al. 2007 (179) 
1035 men and women, 
mean age 51 y,  
population-based 
IDF hsCRP increased with the increase of 
MS components. hsCRP was stronger 
indicator of MS in women.   
Florez H 
et al. 2006 (178) 
190 men and women, 
mean age 53 y, 
selected subjects
NCEP Those with MS had higher hsCRP. 
Higher hsCRP concentrations were in 
those with abdominal obesity. 
Wannamethee S 
et al. 2005 (172) 
2722 men,  
age 60-79 y,  
from practice registers 
NCEP
WHO, 
modified 
Men with MS based on NCEP and 
WHO had higher concentrations of 
hsCRP and markers of haemostasis. 
Santos A-C 
et al. 2005 (175) 
957 men and women,  
mean age 53 y,  
random digit dialing-one 
adult per household 
NCEP Those with MS had higher hsCRP. 
Central obesity and blood pressure 
were important determinants of 
inflammation in the MS. 
Lim S 
et al. 2005 (176) 
9773 men and women,  
age 40-69 y, from rural  
and urban community  
NCEP
for Asian 
The highest quartile of hsCRP was 
independently associated with 2 times 
higher risk of having MS.  
Ford E 
et al. 2005 (177) 
1366 men and women, 
age 12-17 y, data from 
NHANES 1999-2000 
NCEP Those with MS had higher hsCRP. Of 
those with MS 38 % had hsCRP 
concentration >3 mg/l.  
Lee W-Y 
et al. 2004 (174) 
767 men and women,  
mean age 47 y, 
selected subjects 
NCEP Those with MS had 2 times higher 
hsCRP. Of the MS components waist 
girth correlated best with hsCRP.  
Rutter M 
et al. 2004 (173) 
1356 men 1681 women,  
mean age 54 y, 
community-based 
NCEP Those with MS had higher hsCRP. 
hsCRP was higher in women with MS 
than in men with MS. 
Browning LM 
et al. 2004 (185) 
257 women,  
mean age 46 y, BMI>25, 
community-based 
WHO hsCRP was not associated with MS 
independently of BMI. 
CVD=cardiovascular disease, BMI=body mass index, y=years, NCEP=National Cholesterol Education 
Program, WHO=World Health Organization, IDF=International Diabetes Federation, NHANES= 
National Health and Nutrition Examination Survey. 
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2.2.8 Endothelial dysfunction 
Several components of the metabolic syndrome impair endothelial function (186). A
primary feature of endothelial dysfunction is the reduced bioavailability of nitric oxide 
which has an important role in vascular relaxation and important anti-atherogenic 
properties (187). Insulin resistance and systolic blood pressure are the principal 
determinants of endothelial dysfunction in the metabolic syndrome (186,188). 
Imbalanced production of fat-derived metabolic products, hormones and cytokines in 
obesity (especially visceral) decrease insulin sensitivity in the liver and skeletal muscle 
and impair endothelial function through direct or indirect mechanisms (186,189). In the 
insulin-resistance state, the ability of insulin to stimulate nitric oxide production in the 
endothelium is diminished (186). In obese individuals, endothelium-dependent 
vasodilatation may be reduced by up to 50% compared with lean subjects (190). High 
plasma levels of triglycerides (191) and total and LDL cholesterol, even at the levels 
with the normal range, may cause endothelial dysfunction (192). IGT and type 2 
diabetes are also associated with impaired endothelium-dependent vasodilatation (193). 
Aging represents an independent risk factor for endothelial dysfunction (194,195).
2.3 Genetic susceptibility to the metabolic syndrome 
Family studies suggest a significant genetic basis to individual components of the 
metabolic syndrome, such as abdominal obesity, insulin resistance, HDL cholesterol, 
triglycerides, and blood pressure (196,197). Clustering of the syndrome in families 
suggests also a genetic basis for the metabolic syndrome itself (197). Family studies 
demonstrate that clustering of metabolic risk factors are transmitted from parents to 
offspring (196,198). The thrifty gene hypothesis suggests that genetic selection has 
favoured energy-conserving genotypes in environment with an unstable food supply. 
Storage of energy as fat rather than glycogen would ensure energy during periods of 
starvation (197). To expose such genotypes to an abundance of food is detrimental, and 
may thus predispose to the metabolic syndrome and glucose intolerance (197). An 
alternative explanation, the thrifty phenotype, suggests that intra-uterine malnutrition 
leads to a low birth weight and increases the risk of the metabolic syndrome in later life 
(197). The risk of the metabolic syndrome associated with low birthweight has been 
34
shown to increase particularly in families with the metabolic syndrome, suggesting that 
a low birthweight could be a phenotype for a thrifty gene (197) 
 
2.4 Metabolic syndrome and preclinical atherosclerosis 
Atherosclerosis is a progressive disease resulting from endothelial dysfunction, 
inflammation, lipid accumulation and thrombosis (199). The arterial intima-media 
represents the site for the development of atherosclerotic lesions. Although 
atherosclerosis is a generalized disease, specific arterial sites, such as bifurcations are 
prone to atherosclerotic plaque formation (199). High-resolution B-mode 
ultrasonography has been used to obtain measurements of the thickness of the intima 
and media of the carotid arteries. Carotid artery IMT is a surrogate measure of global 
preclinical atherosclerosis and predicts future risk of myocardial infarction and stroke 
(200,201). A change in carotid IMT has been validated as a vascular marker of the 
progression of preclinical atherosclerosis (202). 
In prospective studies, individual components of the metabolic syndrome, such as 
abdominal obesity (47), elevated blood pressure (203-205), high triglycerides (204), low 
HDL cholesterol (204), and elevated blood glucose (206) have been found to associate 
with preclinical atherosclerosis as assessed by carotid IMT. 
Many cross-sectional studies (106,207-214) (Table 5) have shown an association of 
metabolic syndrome with carotid IMT. In some, the effect was more pronounced in 
women than in men (210,212). Few prospective studies have assessed the relation of the 
metabolic syndrome to carotid IMT (Table 5). In a 5-year study, men and women with 
the metabolic syndrome had an increased risk of developing carotid atherosclerosis 
(215). In a 3-year study, men with the metabolic syndrome during the study had greater 
carotid IMT at both baseline and after 3 years (216). Also, individuals with multiple 
cardiovascular risk factors at baseline had a greater carotid IMT 15 years later (204). 
Because both cross-sectional and follow-up studies have been performed mainly in 
middle-aged individuals or had a wide age range, data from elderly population are 
warranted. Also, there is a lack of long term studies that focus on association of 
development of the metabolic syndrome with change in carotid IMT. 
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Table 5. Epidemiological studies on the association of metabolic syndrome (MS) with carotid intima-
media thickness (IMT) 
Author Study design Definition Result 
prospective
Hassinen M 
et al. 2006
(part of thesis, 
Study IV) 
101 women, 
age 60-70 y, 
population-based, 12 y 
NCEP The mean increase in carotid IMT was 
2 times greater in those who developed 
MS than those who did not. 
Fan AZ  
2006 (217) 
573 men and women, 
age 40-60 y,  
employees from a local 
utility company, 3 y 
Factor
analysis
The atherogenic effects of MS were 
mediated through its indicators. The 
association between MS variables and 
IMT differed between sexes. 
Wallenfeldt K 
et al. 2005 (216) 
316 men , age 58 y,  
selected based on obesity 
and insulin sensitivity, 3 y 
WHO, 
modified 
NCEP
Both initial and final IMT was greater 
in men with MS according to WHO or 
NCEP. The annual change in IMT was 
greater in men with WHO MS both at 
baseline and after 3 years. 
Bonora E 
et al. 2003 (215) 
888 men and women,  
age 40-79 y,  
population-based, 5 y 
WHO 
NCEP
Those with MS according to WHO or 
NCEP had an increased incidence of 
IMT plaque (WHO 51/NCEP 47%) and 
stenosis (WHO 34/NCEP 42%).  
cross-sectional
Vaudo G 
et al. 2007 (214) 
234 men and women,  
mean age 53 y,  
147 outpatients with MS,  
87 controls from staff 
NCEP Patients with MS had greater carotid 
and femoral IMT and altered 
endothelial function.  
Sandhofer A  
et al. 2007 (213) 
1518 men (40-60 y) and 
women (50-70 y), 
population-based 
NCEP
WHO 
IDF
Subjects with MS had greater IMT than 
those without MS.  
Kawamoto R 
et al. 2007 (212) 
868 men and women,  
mean age 64 and 70 y, 
hospitalized patient 
Own 
modified 
definition  
Subjects with MS had greater IMT than 
those without MS. The effect was more 
pronounced in women.  
Mohan V 
et al. 2006 (211) 
3430 men and women, 
mean age 45 y,  
population-based 
NCEP, 
modified 
Subjects with MS had greater IMT than 
those without MS. IMT increased with 
severity of glucose intolerance.  
Iglseder B 
et al. 2005 (210) 
1588 men and women,  
age 40-65 y, unrelated, 
healthy; from a clinic 
NCEP Subjects with MS had higher IMT than 
those without MS. The effect of MS 
was more pronounced in women.  
Scuteri A 
et al. 2004 (208) 
471 men and women,  
age 21-96 y, volunteers 
NCEP Subjects with MS had 16 % higher 
IMT values than those without MS.   
McNeill A 
et al. 2004 (209) 
14502 men and women,   
age 45-64 y,  
population-based 
NCEP Subjects with MS had greater IMT and 
were 2 times more likely to have CHD 
than those without MS.  
Golden S 
et al. 2002 (207) 
11790 men and women, 
age 45-64 y, 
population-based 
Six insulin 
resistance
components 
Those with all six risk factors had 
greater IMT than those without this 
grouping.  
Hulthe J 
et al. 2000 (106) 
391 men,  
age 58 y,  
population-based 
WHO Subjects with MS had greater IMT 
values and more small LDL particles 
than those without MS.  
CHD=coronary hearth disease, NCEP=National Cholesterol Education Program, WHO=World Health 
Organization, IDF=International Diabetes Federation, y=years. 
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2.5 Prevention and treatment of the metabolic syndrome 
2.5.1 Physical activity 
The NCEP Adult Treatment Panel III guidelines for the treatment of the metabolic 
syndrome recommended that after medical control of LDL cholesterol, the first-line 
treatment of the metabolic syndrome should be weight reduction and increased physical 
activity (218). Also other expert groups consider physical activity, diet and weight 
control as cornerstones in the prevention and treatment of the metabolic syndrome 
(219,220). Current evidence supports recommendation from the Centers for Disease 
Control and Prevention of the United States and the American College of Sports 
Medicine in 1995 (221), updated in 2007 with more accurate recommendations for 
different intensity and type of activities in all healthy adults aged 18 to 65 years (222) 
and in older adults (223). Based on these recommendations, to promote and maintain 
health, all healthy individuals should engage at least 30 minutes of moderate aerobic 
physical activity on five days each week or vigorous-intensity aerobic physical activity 
at least 20 minutes on three days each week and perform activities that maintain or 
increase muscular strength and endurance at least two days each week. In addition for 
older adults, the recommendations emphasize flexibility and balance exercises. 
Randomized controlled trials indicate that exercise training has positive effects on 
individual components of metabolic and cardiovascular risk factors related to the 
metabolic syndrome such as body weight and fat (224-226), insulin sensitivity 
(226,227), lipid profile (228), blood pressure (229-231), low-grade inflammation 
(232,233), and diabetes (234). In all above mentioned trials, the follow-up periods were 
relatively short, 4-52 weeks, with the exception of the 6-year DNASCO (DNA 
Polymorphisms in Carotid Atherosclerosis) Study (230,232). 
Current evidence on the effect of physical activity in the prevention of the metabolic 
syndrome itself is based mainly on cross-sectional (132,134,136,235,236) and 
prospective (137,140,237) epidemiological and short intervention (238) studies, 
suggesting that regular aerobic physical activity (137,140,235,236,238), muscular 
strength (134,136,237) and good cardiorespiratory fitness (132,137) are associated with 
or reduce the risk of developing the metabolic syndrome. In a randomized controlled 
trial of volunteers with IGT, a three-year lifestyle intervention including diet and 
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moderate intensity physical activity decreased the incidence of the metabolic syndrome 
by 41% compared with the placebo group (239). 
The favorable effects of physical activity on most metabolic and cardiovascular risk 
factors are stronger if associated with weight loss (240). There are also individual 
differences of the effect of exercise on risk factors influenced by age, sex and genetic 
factors (122). 
 
2.5.2 Nutrition 
In addition to exercise, diet can also be beneficial for many of the components of the 
metabolic syndrome. In a recent meta-analysis of 44 randomized controlled trials, diet 
combined with exercise reduced body mass index and blood pressure, and the reduction 
of blood pressure was greater with diet alone than with exercise alone (231). In a 
randomized trial in obese men, adding structured exercise to diet counselling did not 
ameliorate the metabolic syndrome better than diet only (241). Another meta-analysis of 
randomized controlled trials found that combination of diet and exercise or solely 
dietary intervention was effective for reducing risk for type 2 diabetes in high risk 
individuals (242). Large cohort (243-245) and intervention (246) studies suggest that 
diets low in saturated fat, high in fiber, rich in fruits and vegetables, and with a low 
glycemic index may decrease the risk for diabetes or CVD. These findings give 
evidence that such diets may be effective for reducing the risk of the metabolic 
syndrome, but intervention studies are needed. 
2.5.3 Weight reduction 
Weight reduction is one of the key elements in preventing and treating of the risk 
factors of the metabolic syndrome. Epidemiological prospective studies and clinical 
trials have shown that even modest weight reduction of 5-10 %, due to either an 
increase in physical activity or a decrease in energy intake or both, can substantially 
lower blood pressure, improve blood lipid profile, insulin sensitivity and glucose 
tolerance (247) and decrease the incidence of diabetes (246). In a short-term 
randomized controlled trial, for each 1 kg of weight lost, the likelihood of the metabolic 
syndrome were reduced by 8 % in obese men and women (248). 
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2.5.4 Medication 
At present, drug therapy for the metabolic syndrome focuses on correction of the 
individual risk factors i.e. hypertension, dyslipidemia, adiposity and hyperglycemia 
(1,25). Treatment guidelines have been given by the NCEP (20,218), the Sixth Joint 
National Committee for blood pressure (249) and the American Hearth 
Association/American College of Cardiology (250). In a randomized trial of volunteers 
of the effect of metformin or lifestyle intervention on the metabolic syndrome, the 
incidence of metabolic syndrome was reduced by 41% in the lifestyle group and by 17% 
in the metformin group compared with the placebo group (239). 
2.6 Summary of the review 
The metabolic syndrome is a group of risk factors of metabolic origin accompanied by 
an increased risk for type 2 diabetes and CVD. The increasing prevalence of the 
metabolic syndrome is largely due to increasing obesity throughout the world. Several 
factors are likely to contribute to susceptibility to the metabolic syndrome, especially 
genes, aging, sedentary lifestyle and an atherogenic diet. The two putative main 
underlying risk factors for the metabolic syndrome are abdominal obesity and insulin 
resistance (Figure 3). 
 Insulin resistance can be secondary to obesity, but can have genetic components as 
well. Hyperinsulinemia may also be a risk factor for development of obesity. Metabolic 
syndrome is also characterized by elevated fasting plasma glucose levels. Another 
component of the metabolic syndrome, dyslipidemia, comprises elevated triglycerides 
and low levels of HDL cholesterol. Also, plasma LDL cholesterol particles are smaller 
than normal, making them more atherogenic. Elevated blood pressure is strongly 
associated with obesity and occurs more often in insulin-resistant individuals. Several 
other factors are postulated to contribute to the syndrome. A proinflammatory state is 
commonly present in the metabolic syndrome, largely due to obesity, and is 
characterized by elevation of cytokines and acute phase reactants, e.g. CRP. The 
prothrombotic state in the metabolic syndrome is characterized by elevation of 
fibrinogen and PAI-1. Several components of the metabolic syndrome have an adverse 
impact on the vascular endothelium, producing endothelial dysfunction and favoring the 
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progression of atherosclerosis. A better understanding of the non-traditional risk factors 
for the metabolic syndrome is still needed, especially in the elderly. For example, what 
is the additive value of low cardiorespiratory fitness, chronic low-grade inflammation 
and preclinical atherosclerosis in the prediction of the metabolic syndrome? Evidence 
from epidemiological and randomized trials supports the positive role of physical 
activity, healthy diet and weight control in prevention and treatment of the individual 
components of the metabolic and cardiovascular risk factors. The optimal prescription 
of physical exercise or diet is still unknown. 
                     A d i p o s i t y 
I n s u l i n   r e s i s t a n c e 
G l u c o s e  i n t o l e r a n c e
D y s l i p i d e m i a 
E l e v a t e d   b l o o d   p r e s s u r e
Figure 3. The interaction and timeorder of the individual components of the metabolic 
syndrome. 
40
3. AIMS OF THE STUDY 
 
The purpose of the present thesis based on two population studies is to increase the 
understanding of the predictors and consequences of the metabolic syndrome in aging 
men and women. Special emphasis is on the associations of physical fitness and low-
grade inflammation with the metabolic syndrome and on the association of the 
metabolic syndrome with the progression of carotid IMT during 12 years. 
The specific aims of the study are to investigate: 
1. The association of poor cardiorespiratory fitness with the metabolic syndrome and 
impaired glucose homeostasis in older men and women (Study I). 
2. The association of serum hsCRP with development of the metabolic syndrome in 
elderly women during a 12-year follow-up (Study II). 
3. Associations of hip and waist circumferences with the progression of carotid 
atherosclerosis, quantitated ultrasonographically by carotid IMT, in elderly women 
during a 12-year follow-up (Study III). 
4. The association of incident metabolic syndrome with the progression of carotid 
atherosclerosis as measured by carotid IMT, in elderly women during a 12-year follow-
up (Study IV). 
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4. METHODS 
 
4.1 Study populations and design 
The data used in this thesis are from two population-based studies from Eastern Finland 
(Table 6). In Study I, the men and women were 57-79 years of age. In Studies II-IV, the 
women were 60-70 years of age at baseline of the 12 years follow-up. 
Table 6. Study population and design of the Studies I-IV 
Study Study 
population 
Study design Risk factor Outcome 
I 1347 men 
and women 
baseline of 
a RCT1
Poor
cardiorespiratory 
fitness 
Impaired glucose 
tolerance and 
metabolic syndrome 
II 103 women prospective
cohort, 12 years 
Low-grade
inflammation2
Metabolic syndrome3
III 102 women prospective
cohort, 12 years 
Obesity Carotid
atherosclerosis4
IV 101 women prospective
cohort, 12 years 
Metabolic 
syndrome3
Carotid
atherosclerosis4
1 Ongoing randomized controlled trial, DR’s EXTRA Study 
2 Change in high-sensitivity C-reactive protein during 12 years 
3 Incident metabolic syndrome during 12 years 
4 Change in carotid IMT during 12 years 
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Study I  
The subjects were participants of the Dose-Responses to Exercise Training (DR’s 
EXTRA, ISRCTN45977199) Study, the ongoing randomized controlled 4-year trial on 
the effects of regular physical exercise and diet on endothelial function, atherosclerosis 
and cognition. In the present study we used the baseline data of the study (Figure 4). 
The original subject source was derived from a population register in 2002. The 
subjects were a representative sample of 1500 men and 1500 women, aged 55 to 74 
years, from the city of Kuopio in Eastern Finland. Of these individuals, 2062 expressed
their willingness to participate in the study. Altogether 1479 participated in the baseline 
examinations between April 2005 and November 2006, and 1410 of them participated 
in all the baseline study visits and were randomized into study groups (Figure 4).  
Exclusion criteria for the intervention study were conditions that inhibit safe 
engagement in exercise training, malignant diseases and other conditions preventing co-
operation, as judged by the research physicians. The present study population consisted 
of 1347 subjects (671 men, 676 women) who had complete data on VO2max, glucose 
homeostasis and the characteristics of the metabolic syndrome, and did not have type 1 
diabetes. Of these individuals 564 men, 613 women did not have type 2 diabetes. The 
study protocol was approved by the Ethics Committee of Kuopio University and 
University Hospital. All participants gave written informed consent. 
Those 37 men and 32 women who did not participate in all the baseline visits and 
were thus excluded based on partial data were older (69.7 vs. 66.5 years, P<0.001), less 
educated (8.9 vs. 11.2 years, P<0.001), shorter (163.2 vs. 166.7 cm, P=0.02), had a 
lower VO2max (16.0 vs. 23.6 ml·kg
-1·min-1, P<0.001), and serum HDL cholesterol (1.5 
vs. 1.7 mmol/l, P=0.002), higher weight (81.9 vs. 77.1 kg, P=0.05), larger waist (102.2 
vs. 93.9 cm, P<0.001) and hip circumference (107.4 vs. 100.9 cm, P<0.001), higher 
body mass index (30.7 vs. 27.7, P<0.001), fasting plasma glucose (6.3 vs. 5.8 mmol/l, 
P=0.003), serum triglycerides (1.6 vs. 1.3 mmol/l, P=0.03), and more metabolic risk 
factors (2.4 vs. 1.9, P=0.001). They were more likely to have metabolic syndrome (43 
vs. 26%, P=0.008), CVD (50 vs. 22%, P<0.001), worse glycemic status (IGR 26 vs. 
21% and type 2 diabetes 22 vs. 13%, P=0.04) and worse smoking status (never 40 vs. 
55%; former smokers 36 vs. 35% and current smokers 24 vs. 11%, P=0.003). 
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Original subject source of men and women aged 55-74 years in 2002 
                            n=16 010 
 
Figure 4. DR’s EXTRA Study design (Study I) 
n=3000 
Random sample of men and women 
invited to the study in 2002 
n=2062
Willing to participate 
                           n=1829 
Invited to the baseline examinations 
in 2005 
                            n=1479  
Participated in the baseline examinations 
in 2005-2006 
Death                              24 
CVD                               12 
Cancer                            12 
Dementia                          4 
Musculoskeletal disease 15 
Other disease                  29 
Loss of motivation       126 
Moved elsewhere           38 
Unknown reasons           84 
Unreachable                     6
                           n=1410 
Randomization into intervention groups 
Subjects for Study I
CVD                              18 
Dementia                         1 
Musculoskeletal disease  8 
Other disease                 19 
Loss of motivation        22 
Moved elsewhere            1 
Run-in phase in 2003-2005 
Death                               9 
CVD                                3 
Cancer                             2 
Dementia                         3 
Musculoskeletal disease 4 
Other disease                 27 
Loss of motivation        59 
Moved elsewhere          20 
Unknown reasons        103 
Unreachable                    3 
Reference Aerobic 
Exercise
Dietary Aerobic
+Dietary
Resistance
+Dietary
Death                             20 
Severe disease               48 
Moved elsewhere          13 
Not interested              647 
No response                 210 
Resistance
Exercise
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Studies II-IV 
The subjects were derived from a population-based, randomly selected sample of 299 
women 50 to 60 years of age, initially examined as part of a large population-based risk 
factor study (FINMONICA) in 1982 (251) (Figure 5). The original study sample was 
stratified separately for men and women by ten year age groups to obtain even age and 
gender specific groups. For the baseline examinations of the present study in 1991-
1992, we recruited only women, 60 to 70 years of age, living in province of Kuopio, one 
of the monitoring areas of the Finnish part of the WHO MONICA (Multinational 
Monitoring of Trends and Determinants in Cardiovascular Disease) project. Of the 260 
women who were invited, altogether 202 women completed the examinations between 
October 1991 and March 1992. Because 32 women had died or could not be contacted,
170 women 70 to 80 years of age were eligible for the 12-year follow-up study in 2003 
(Figure 5). Of 170 women who were invited in the follow-up study, 57 did not 
participate.  
All of the 113 women who participated in the study completed the examinations 
between March 2003 and June 2003. The same methods were used to assess study 
variables in study years 1991-1992 and 2003. The women who have participated in both 
study years were included in the analysis. Of the 113 women who completed all study 
visits in 2003, six had missing data on hsCRP at baseline or after follow-up and four 
had hsCRP concentrations >10.0 mg/l at baseline. Thus in Study II, the final study 
population included 103 women. Due to missing data on carotid IMT in either 
examination, the final study sample consisted of 102 women in Study III and 101 
women in Study IV with complete data on study variables (Table 6). The study protocol 
was approved by the Ethics Committee of the University of Kuopio. All participants 
gave a written informed consent. 
Those 89 women who participated in 1992, but did not participate in the 12 year 
follow-up in 2003 were older (65.6 vs. 63.9 years, P<0.001) and less educated (7.0 vs. 
8.5 years, P=0.004) and had higher body weight (72.4 vs. 67.9 kg, P=0.003) and body 
mass index (29.2 vs. 27.4, P=0.004), a larger waist (88.0 vs. 83.4 cm, P= 0.002) and hip 
circumference (102.0 vs. 98.8 cm, P=0.03), higher triglycerides (1.6 vs. 1.2 mmol/l, 
P=0.008), systolic blood pressure (161.3 vs. 155.5 mm Hg, P=0.05) and diastolic blood 
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pressure (91.9 vs. 88.5 mm Hg, P=0.02), lower HDL cholesterol (1.5 vs. 1.6 mmol/l, 
P=0.02), more metabolic risk factors (2.1 vs. 1.6, P<0.001) and a higher prevalence of 
type 2 diabetes (5 vs. 0 %, P=0.02) at baseline than the participants. 
Finmonica in 1982 
n=299
Figure 5. Formation of the cohort of the 12-year follow-up study (Studies II-IV) 
Invited in 1992 
n=260
Home visit (1993)              42 
Lost to follow-up               16 
Follow-up in 1992 
n=202
Baseline of Studies II-IV
No contact information        5 
Death                                  27 
Invited in 2003
n=170
Lost to follow-up               23 
Death                                 16 
Death                                    4 
Stroke                                   1 
Cancer                                  1 
Dementia                              2 
Musculoskeletal disease     11 
Other health problems        18 
Loss of motivation               8 Follow-up in 2003 
Transportation problems    10 n=113
Other reasons                       2 
12-year follow-up of Studies II-IV
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EXAMINATION PROTOCOL 
Study I 
Examinations were carried out over three days, about seven days apart. The examination 
protocol consisted of a wide variety of examinations including anthropometry, 
biochemistry, measurement of blood pressure, endothelial function and 
cardiorespiratory fitness, carotid ultrasound, muscle and adipose tissue biopsies, 
assessment of cognitive function, depression, functional capacity and nutrition, and 
questionnaires on physical activity and background information. The invitation letter 
consisted general information about the study, instructions for laboratory measurements 
and a questionnaire on background information. For those who did not respond to the 
invitation letter, a phone call was made to determine the reason for non-participation. 
The study visits and the measurements used in the Study I are presented here. At the 
first visit, the subjects gave blood samples for laboratory determinations. Before these 
measurements they were instructed to fast 12 hours and to abstain from drinking alcohol 
for three days, from smoking for 12 hours and from hard physical activity for a day. At 
the same visit anthropometry and blood pressure were measured and the subjects 
returned the self-administered questionnaire of background information. At the second 
visit, the returned questionnaire was checked and completed. At the third visit, a 
maximal cycle ergometer exercise test was performed. After these three visits, a 2-hour 
oral glucose tolerance test (OGTT) was performed to those who met specific criteria 
(see 4.3). 
 
Studies II-IV 
Baseline visits 
Examinations were carried out over four days, at least eight days apart. The examination 
protocol consisted of a wide variety of examinations including anthropometry, 
biochemistry, measurement of blood pressure and bone mineral density, carotid 
ultrasound, assessment of cognitive function  and functional capacity, and 
questionnaires on physical activity, nutrition, symptoms of depression and background 
information.  
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The study visits and the measurements used in the Studies II-IV are as follows. At 
the first visit, the women brought the completed questionnaire on background 
information, which was mailed before and a study nurse checked the questionnaire at 
that time. At the second visit, the women gave blood samples for laboratory 
determinations. Before these measurements the women were instructed to fast 12 hours 
and to abstain from drinking alcohol and using analgesics (except paracetamol) for a 
week. At the same visit, the questionnaire on physical activity was given to complete at 
home. At the third visit, a trained nurse measured carotid IMT, anthropometry and 
blood pressure and physical activity questionnaire was received. 
 
12-year follow-up visits 
Examinations were carried out over two days, at least eight days apart. The examination 
protocol consisted of a wide variety of examinations including anthropometry, 
biochemistry, measurement of blood pressure, carotid ultrasound, assessment of 
cognitive function and functional capacity, and questionnaires on depression, nutrition, 
physical activity and background information. Invitation letter consisted general 
information of the study. Among those who did not response an invitation letter, a 
phone call was made to determine the reason for non-participation. 
At the first visit, the women gave blood samples for laboratory determinations. 
Before these measurements the women were instructed to fast 12 hours and to abstain 
from drinking alcohol using analgesics (except paracetamol) for a week. At the same 
visit, carotid artery ultrasonography was performed. A self-administered questionnaire 
of background information was given to complete at home. At the second visit 
antropometry and blood pressure were measured. A nurse received and checked the 
self-administered questionnaire and interviewed their physical activity during the last 
month. 
 
4.2 Assessment of body composition 
Anthropometric measurements were assessed based on the MONICA protocol (252) 
with the subject in light indoor clothing without shoes. Body height (accuracy 0.1 cm) 
was measured using a metal scaled height meter. Body weight (accuracy 0.1 kg) was 
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measured with a digital scale. Body mass index was calculated dividing body weight in 
kilograms by the square of body height in meters. Waist circumference (accuracy 0.5 
cm) was measured on bare skin, mid-distance between the bottom of the rib cage and 
the top of the iliac crest. Hip circumference (accuracy 0.5 cm) was measured at the level 
of the trochanter major. Subjects stood with their feet 12 cm apart with their weight 
equally distributed on each leg. The mean of two measurements of the circumferences 
were used in the analyses. The waist-to-hip ratio was calculated as the ratio of the 
circumference of the waist to the hip. 
In the 84 participants at follow-up visit in 2003 (Studies II-IV), intraclass correlation 
between the mean of two measurements of two measurers at the same study visit for 
body height was 0.999 (P<0.0001), waist circumference 0.995 (P<0.0001), and hip 
circumference 0.981 (P<0.0001). Coefficients of variation were 0.7%, 0.7% and 0.5%, 
respectively. 
 
4.3 Assessment of glucose homeostasis 
Venous blood samples were taken without stasis into glass tubes in the morning after a 
12 hour fast by 10 o’clock and the samples were analyzed daily. Hexokinase method 
(Glucose, Thermo Clinical Labsystems Oy, Finland) was used for fasting plasma 
glucose analyses in Study I and fasting blood glucose analyses in Studies II-IV. In 
Study I, a 2-hour OGTT with a 75 g glucose load was carried out in the morning after a 
12-hour fast for individuals with no previously diagnosed diabetes. The blood samples 
were taken at fasting state, and after 30, 60 and 120 minutes of the glucose load. The 
maximum deviation from those time point allowed was ±3 minutes.  
 Based on WHO criteria (18), the subjects were classified as having normal glucose 
tolerance if the fasting plasma glucose was <6.1 mmol/l and 2-hour glucose was <7.8 
mmol/l, IFG if the fasting plasma glucose was between 6.1 and 6.9 mmol/l and 2-hour 
glucose was <7.8 mmol/l, IGT if the fasting plasma glucose was <7.0 mmol/l and 2-
hour glucose was between 7.8 and 11.1 mmol/l and type 2 diabetes if the fasting plasma 
glucose was 7.0 mmol/l or a 2-hour glucose was 11.1 mmol/l. Impaired glucose 
regulation (IGR), defined as the presence of IFG or IGT, refers to an intermediate state 
between normal glucose homeostasis and type 2 diabetes (18). In addition, those 
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subjects who did not participate in the OGTT were classified as having normal glucose 
tolerance if the fasting plasma glucose level was <6.1 mmol/l, IFG if the plasma glucose 
level was between 6.1 and 6.9 mmol/l and diabetes if they reported to have type 2 
diabetes diagnosed by a physician or the fasting plasma glucose level was 7.0 mmol/l. 
 
4.4 Assessment of serum lipids and lipoproteins 
Venous blood samples were taken without stasis into glass tubes in the morning after a 
12 hour fast by 10 o’clock. Serum total cholesterol (Cholesterol, Thermo Electron 
Corporation, Finland in Study I; CHOD-PAP, Roche Diagnostics GmbH, Germany in 
Studies II-IV) and serum triglycerides (Triglycerides, Thermo Electron Corporation, 
Finland in Study I; GPO-PAP, Thermo Clinical Labsystems Oy, Finland in Studies II-
IV) were analyzed by enzymatic photometric methods. Serum HDL cholesterol was 
analyzed using a direct enzymatic photometric method (HDL-Cholesterol, Thermo 
Electron Corporation, Finland) in Study I, and using an enzymatic photometric method 
(CHOD-PAP, Roche Diagnostics GmbH, Germany) in a supernatant after precipitation 
with dextran sulphate and MgCl2 in Studies II-IV. Serum LDL cholesterol was 
calculated according to the Friedewald formula (253) in Studies II-IV and analyzed by a 
direct enzymatic photometric method (LDL-Cholesterol, Thermo Electron Corporation, 
Finland) in Study I. KONE Pro clinical chemistry analyzer (Studies II-IV) and 
KONELAB 20XTi (Study I) were used for analyses. In Study I, the samples were 
analyzed daily. In Study II-IV, the samples were stored in 2-8ºC and analyzed once a 
week at baseline and the 12-year follow-up, except for triglycerides in the 12-year 
follow-up, which were analyzed daily.
 
4.5 Asssessment of low-grade inflammation 
In Study II, serum hsCRP was analyzed by a commercial immunoassay (IMMULITE 
2000 High-Sensitivity CRP, Diagnostic Products Corp., Los Angeles, CA, USA) using 
the IMMULITE 2000 Analyzer (Diagnostic Products Corp.). In the 103 participants, 
intraclass correlations between two hsCRP assays during the same study visit were 
0.999 and 0.998 (P<0.0001 both) and coefficients of variation were 2.8% and 3.4% at 
baseline and after follow-up in 2003, respectively. The within and between assay 
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variations of the hsCRP-method were at a low level (1.6 mg/l) 3.5 and 9.5% and at a 
medium level (4.7 mg/l) 3.9 and 6.2%. Serum samples for hsCRP were taken after 12 
hour fast at baseline and 12-year follow-up and were stored at -80°C until analysis in 
2005. To minimize confounding due to acute infections or other diseases that could 
increase hsCRP concentrations, four women with hsCRP >10.0 mg/l at baseline were 
excluded from analyses. 
 
4.6 Assessment of blood pressure 
Blood pressure in the right arm was recorded in a sitting position after a five minute rest 
using a mercury sphygmomanometer. The first appearance of the sounds (Korotkoff’s 
1st phase) was recorded as the systolic blood pressure and the disappearance of the 
sounds (Korotkoff’s 5th phase) was recorded as the diastolic blood pressure. Two
independent consecutive measurements of systolic and diastolic blood pressure were 
taken, and the mean of the measurements was used. 
 
4.7 Assessment of cardiorespiratory fitness 
In Study I, cardiorespiratory fitness was assessed during a maximal symptom-limited 
exercise test to exhaustion on an electrically-braked cycle ergometer (Ergoline, Bitz, 
Germany). From the final analyses, 59 from 1410 individuals were excluded. Five
individuals were excluded due to measurement error in respiratory gases, 7 individuals 
with submaximal and 40 individuals with indirect testing. Seven individuals were not 
tested due to musculoskeletal or cardiac problems. Furthermore, because 4 individuals 
with type 1 diabetes were excluded from present analyses, the final study population 
was 1347 men and women with complete data on VO2max. For safety reasons, and to 
obtain reliable information about exercise test variables, the tests were supervised by an 
experienced physician with the assistance of an experienced nurse. The test was 
performed using a standardized test protocol with a warm-up of 3 minutes at 20 W and a 
20 W-increase in the workload per minute. Oxygen consumption was measured directly 
by the breath-by-breath method using the VMax respiratory gas analyzer (Sensor 
Medics, Yorba Linda, CA). VO2max was defined as the mean of the three highest values 
of the average oxygen consumption measured consecutively over 20 second intervals 
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and expressed as milliliters of oxygen per kilogram of body weight per minute. A total 
of 98% of the subjects achieved the respiratory exchange ratio of 1.1.
Electrocardiography was recoded before, during and after the exercise test using 
Cardiosoft software (GE Medical Systems, Freiburg, Germany). Reasons for stopping 
the exercise test were recorded for all tested individuals. For those in the present 
analyses, the reasons were leg fatigue (n=694), breathlessness (n=508), exhaustion 
(n=41), joint pain (n=29), dyspnea (n=29), pain in leg muscle (n=20), arrhythmias 
(n=9), ST depression (n=8), a marked increase in systolic blood pressure (n=5), 
dizziness (n=1), signs of cardiac insufficiency (n=1), difficulties in co-operation (n=1), 
and lack of subject motivation (n=1). 
4.8 Definition of metabolic syndrome 
The metabolic syndrome was defined by the National Cholesterol Education Program 
Adult Treatment Panel III (NCEP) criteria (20), based on the presence of elevated blood 
pressure (130/85 mm Hg or drug treatment), increased fasting plasma (Study I) or 
blood (Studies II and IV) glucose (6.1 mmol/l), low HDL cholesterol (<1.03 mmol/l in 
men and <1.29 mmol/l in women), high triglycerides (1.7 mmol/l) and abdominal 
obesity (waist circumference >102 cm in men and >88 cm in women). The existence of 
at least three risk factors was defined as the metabolic syndrome.  
 
4.9 Assessment of carotid atherosclerosis 
Carotid artery atherosclerosis was assessed noninvasively by ultrasonography (232,254) 
(Studies III-IV). Carotid IMT was used as a measure of carotid atherosclerosis in the 
present thesis. Certified sonographers measured carotid IMT while the subject was in 
the supine position, with the head turned 45º from the side being scanned. An 
ultrasound device with a high-resolution 10-MHz transducer was used, following a 
standardized and pretested protocol. In each examination, the sonographer used three 
different standardized scanning angles including lateral (45º from vertical axis), anterior 
(20-30º) and posterior (50-60º) projection. The scannings were recorded on super VHS 
videotape. The same sonographer read the scannings during both study years.
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The sonographer measured the IMT of the far wall 
of the right carotid artery. The IMT measurement 
extended to the longest wall region where the 
lumen-intima and media-adventitia boundaries 
could be clearly identified by an automated edge-
detection program based on the active contour 
(255) (Figure 6). The mean carotid IMT of the 
traced region was used for the statistical analyses. 
We used IMT of the carotid bifurcation as the 
indicator of the progression of atherosclerosis 
because arterial bifurcations are prone to local 
plaque formation (199). Although we did not have 
data on the variability of carotid IMT 
measurements available for this particular cohort of 
elderly women, in another our study (232), using 
exactly the same methodology in middle-aged 
men, the mean difference between replicated 
carotid IMT measurements over six years was 
0,0037 mm. 
Figure 6. Measurement of intima-
media (IM) thickness by 
ultrasound (US). 
ECA=external carotid artery 
ICA=internal carotid artery 
 
 
 
 
4.10 Other measurements
In Study I, the subjects completed a self-administered questionnaire on diseases 
diagnosed or treated by a doctor (no vs. yes), present medications, alcohol consumption 
(doses/previous week) and smoking status (never/former/current). CHD was considered 
present if the subject reported to have prevalent angina pectoris, myocardial infarction, 
coronary artery bypass surgery, or percutaneous transluminal coronary artery 
angioplasty. CVD was considered present if the subject reported CHD, cerebrovascular 
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stroke, transient ischemic attack or lower extremity peripheral artery disease. Type 2 
diabetes was defined according to OGTT or self-report (see 4.3). 
In Studies II-IV, the women completed a self-administered questionnaire on diseases 
diagnosed by a doctor in previous year, family history of diseases, medications in 
previous week, smoking (no vs. yes) and alcohol consumption (doses/previous week). A 
subject was considered to have prevalent CHD if she reported to have angina pectoris or 
myocardial infarction. A subject was considered to have prevalent CVD if she reported 
CHD or cardiac insufficiency. Physical activity was assessed by an interview 
questionnaire. The weekly physical activity time (minutes per week) spent on the most 
common physical activities during the last month was estimated. The Framingham risk 
score (Study IV) was calculated by summing up risk points for age, LDL and HDL 
cholesterol, systolic and diastolic blood pressure, prevalent diabetes, and current 
smoking (256). 
 
4.11 Statistical analyses 
All statistical analyses were performed using SPSS for Windows, Release 11.5 and 
P0.05 was considered significant. For all analyses, the variables for adjustment were 
chosen based on their known association with the dependent and independent variables. 
In additional analyses, by adding individual metabolic risk factors or change in 
individual risk factors separately into the models we wanted to show which of the 
individual risk factors most strongly explained the association in question. Similarly, the 
change in physical activity was used as an additional adjustment in Studies III and IV. 
Differences between groups were analyzed using independent-samples t-test or analysis 
of variance for continuous variables and Ȥ2-test for categorical variables as appropriate. 
To test changes between study years (Studies II and IV) the paired-samples t-test for 
continuous variables and the McNemar test for categorical variables were used. 
Appropriate transformation was used to normalize the distribution when required. When 
the variance and normality assumptions were not met, the Mann-Whitney U test or 
Wilcoxon-test was used. Data are presented as means ± standard deviation (SD) or 
percentages.
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In Study I, VO2max was used as a continuous variable and as a categorical variable 
divided into thirds separately in men and women. The heterogeneity of the means of the 
components of the metabolic syndrome between the thirds of VO2max was tested using 
analysis of covariance. The association of VO2max with the risk of having IGR or the 
metabolic syndrome was estimated using logistic regression analysis, expressed as odds 
ratios (OR) and 95% confidence intervals (CI). As a complementary approach for 
assessing the associations of cardiorespiratory fitness with the metabolic syndrome, 
factor analysis was carried out using the core components of or the factors related to the 
metabolic syndrome and VO2max. Principal component analysis was used for the 
extraction of the initial factors, which were then subjected to promax rotation to 
generate correlated factors. Only factors with eigenvalues >1.0 were retained in the 
analysis. Factors with an eigenvalue >1 indicate a factor accounting for more total 
variance than any original standardized variable. 
In Study II, the trend in hsCRP concentration across groups of women with 0, 1, 2 or 
3-5 metabolic risk factors at baseline was analyzed using the test for linearity. Logistic 
regression analysis was used to calculate OR for the development of metabolic 
syndrome in women with hsCRP concentration increases as compared with those with a 
hsCRP concentration decrease. 
In Study III, waist and hip circumferences were categorized into thirds and body 
mass index according to generally used clinical cut-off points (<25, 25-30, and >30) 
(29). Associations between measurements of body composition were analyzed with 
Pearson’s correlation coefficients. The heterogeneity of the means of the 12-year 
increase in carotid IMT between the groups of baseline waist and hip circumferences, 
waist-to-hip ratio, and body mass index was tested using analysis of covariance, and 
expressed as means and 95% CI. For the analyses of interaction between waist and hip 
circumferences on the progression of carotid IMT, waist and hip circumferences were 
dichotomized at mean (83 cm for waist and 98 cm for hip) because of the limited 
number of subjects.
In Study IV, analysis of covariance was used to compare the change in mean carotid 
IMT in women with or without incident metabolic syndrome and also in women with no 
increase, an increase of one or an increase at least two metabolic risk factors during the 
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follow-up. Linear regression analysis was used to assess the independent association of 
individual metabolic risk factors at baseline with the change in carotid IMT.
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5. RESULTS 
 
5.1 Characteristics of the study populations
5.1.1 Study I
In the baseline of the DR’s EXTRA Study, men had higher waist circumferences, 
VO2max, triglycerides, diastolic blood pressure, alcohol consumption, lower HDL 
cholesterol, worse glucose tolerance and higher prevalence of smoking and CVD than 
women (Table 7). Women had a larger hip circumference and higher systolic blood 
pressure and total cholesterol. 
Table 7. Basic characteristics for men and women and differences between sex (Study I) 
Men 
(671) 
Women 
(676) 
P for 
difference 
Age, year  66.3 (5.4)   66.5 (5.3)   0.402 
Height, cm 173.6 (6.1) 160.0 (5.8) <0.001 
Weight, kg     83.6 (13.6)    70.5 (12.9) <0.001 
Body mass index   27.7 (4.0)  27.5 (4.9)   0.544 
Waist circumference, cm    98.9 (11.1)    88.6 (13.0) <0.001 
Hip circumference, cm  99.8 (8.0) 101.8 (9.7) <0.001 
VO2max, ml·kg
-1·min-1  26.4 (6.3)  20.9 (4.9) <0.001 
Alcohol consumption, doses/week    6.3 (8.1)    2.3 (4.3) <0.001 
Smoking, never/ past/ current,  % 35 / 51 / 15 74 / 19 / 7 <0.001 
Fasting plasma glucose, mmol/l    6.0 (1.0)    5.6 (0.8) <0.001 
Serum total cholesterol, mmol/l    4.9 (0.9)    5.3 (0.9) <0.001 
Serum LDL cholesterol, mmol/l    3.2 (0.8)    3.2 (0.8)   0.113 
Serum HDL cholesterol, mmol/l    1.5 (0.4)    1.9 (0.5) <0.001 
Serum triglycerides, mmol/l    1.4 (0.8)    1.3 (0.6)   0.046 
Systolic blood pressure, mm Hg   145.5 (18.9)  150.2 (21.1) <0.001 
Diastolic blood pressure, mm Hg   84.3 (9.4)  82.4 (9.1) <0.001 
IFG/ IGT/ type 2 diabetes, % 14 / 12 / 16 7 / 11 / 9 <0.001 
Cardiovascular disease, % 27 18 <0.001 
Lipid lowering medication, % 35 34   0.672 
Antihypertensive medication, % 41 42   0.785 
Metabolic risk factors, no. 1.9 (1.1)    1.8 (1.2)   0.284 
Metabolic syndrome, % 27 25   0.312 
Data are presented as means (± SD) or percentages (%). P-values from independent-samples t-test, Mann-
Whitney test or Ȥ2-test as appropriate. For glucose and triglycerides P-values were derived from log-
transformed values. Body mass index was calculated as weight (kg) divided by height (m) squared.  
IFG; impaired fasting glucose, IGT; impaired glucose tolerance. 
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5.1.2 Studies II-IV
Basic characteristics of all 113 women who participated both in 1992 and after 12 years 
follow-up in 2003 are presented in Table 8. Whereas waist and hip circumference, body 
mass index, blood glucose, metabolic risk factors and the mean carotid IMT increased, 
LDL and HDL cholesterol and systolic and diastolic blood pressure decreased during 12 
years. Simultaneously, use of lipid lowering and antihypertensive medication increased 
significantly as did the prevalence of metabolic syndrome. The amount of physical 
activity also increased. None of the 113 participants had diabetes diagnosed by a doctor 
at baseline, but 13 developed type 2 diabetes during 12 years. 
 
Table 8. Basic characteristics in 1992 and 2003 of  all 113 women who participated in both study years 
(Studies II-IV). P-value refers to the change during 12 years 
Baseline 
in 1992 
Follow-up 
in 2003 
P for 
difference 
Age, year  63.9 (3.1)   75.3 (3.0) <0.001 
Height, cm 157.6 (5.3) 155.5 (5.5) <0.001 
Weight, kg     67.9 (10.7)    68.4 (12.1)   0.354 
Body mass index   27.4 (4.4)   28.1 (4.9)   0.002 
Waist circumference, cm     83.4 (10.6)     91.8 (11.6) <0.001 
Hip circumference, cm     98.8 (10.3) 102.9 (8.7) <0.001 
Physical activity, min/week    196.6 (109.9)     283.1 (142.2) <0.001 
Alcohol consumption, doses/week    0.6 (1.3)     0.7 (1.6)   0.685 
Smoking, current, % 7 4   0.219 
Fasting blood glucose, mmol/l    4.8 (0.6)    5.3 (1.0) <0.001 
Serum total cholesterol, mmol/l    6.2 (1.0)    5.3 (0.9) <0.001 
Serum LDL cholesterol, mmol/l    4.1 (0.9)    3.5 (0.8) <0.001 
Serum HDL cholesterol, mmol/l    1.6 (0.3)    1.3 (0.3) <0.001 
Serum triglycerides, mmol/l    1.2 (0.4)    1.2 (0.5)   0.399 
High-sensitivity C-reactive protein, mg/l*    2.7 (7.2) 2.4 (3.4)   0.643 
Systolic blood pressure, mm Hg  155.5 (21.9)  141.7 (19.5) <0.001 
Diastolic blood pressure, mm Hg    88.5 (10.1)  71.9 (9.6) <0.001 
Cardiovascular disease, % 17 30   0.001 
Lipid lowering medication, % 6 34 <0.001 
Antihypertensive medication, % 24 55 <0.001 
Metabolic risk factors    1.5 (0.9)     2.4 (1.1) <0.001 
Metabolic syndrome, % 13 48 <0.001 
Carotid intima-media thickness, mm**        1.05 (0.31)         1.26 (0.38) <0.001 
Data are presented as means (± SD) or percentages (%). P-values from paired-samples t-test, Wilcoxon-
test or McNemar test as appropriate. For C-reactive protein P-value was derived from log-transformed 
value. Body mass index was calculated as weight (kg) divided by height (m) squared.*n=107, **n=103 
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5.2 Cardiorespiratory fitness and the metabolic syndrome (Study I) 
Men and women with the metabolic syndrome had, by definition, a high risk factor 
profile (Table 9) and were also more likely to use antihypertensive and lipid lowering 
medication. Also, men with the syndrome were more likely to smoke than those without 
the syndrome.  
 
Table 9. Basic characteristics according to metabolic syndrome status for men and women  
 MEN  WOMEN 
No
 metabolic 
 syndrome 
 Metabolic 
 syndrome 
P for 
difference 
 No    
 metabolic 
 syndrome 
 Metabolic 
 syndrome 
P for 
difference 
N 487 184 507 169
Age, year   66.4 (5.4)   65.9 (5.6)   0.272   66.6 (5.3)   66.4 (5.3)   0.607 
Height, cm 173.5 (6.0) 173.8 (6.2)   0.582 160.0 (6.0) 160.0 (5.4)   0.985 
Weight, kg    79.7 (10.9)    93.8 (14.7) <0.001    66.6 (10.0)    82.2 (13.6) <0.001
Body mass index  26.4 (3.0)   31.0 (4.3) <0.001   26.0 (3.8)  32.1 (4.9) <0.001
Waist circumference, cm  95.3 (8.9)  108.6 (10.7) <0.001    84.3 (10.4)  101.6 (11.1) <0.001
Hip circumference, cm  97.7 (6.5) 105.4 (8.8) <0.001  99.0 (7.9)  110.2 (10.0) <0.001
VO2max, ml·kg
-1·min-1   27.8 (6.1)   22.7 (5.4) <0.001   21.8 (4.9)   18.1 (3.6) <0.001
Alcohol consumption, doses /week    6.3 (7.9)    6.5 (8.4)   0.510    2.4 (4.7)     1.8 (2.9)   0.398 
Smoking, never/ past/ current, % 39 / 49 / 12 23 / 56 / 21 <0.001 74 / 19 / 7 73 / 19 / 8   0.778 
Fasting plasma glucose, mmol/l    5.7 (0.6)    6.7 (1.3) <0.001    5.4 (0.5)    6.3 (1.2) <0.001
Serum total cholesterol, mmol/l    4.9 (0.9)    4.8 (1.0)   0.332    5.3 (0.9)    5.1 (1.0)   0.037 
Serum LDL cholesterol, mmol/l    3.2 (0.8)    3.2 (0.9)   0.991    3.2 (0.8)    3.3 (0.9)   0.664 
Serum HDL cholesterol, mmol/l    1.6 (0.4)    1.2 (0.3) <0.001    2.0 (0.5)    1.5 (0.4) <0.001
Serum triglycerides, mmol/l    1.2 (0.5)    2.0 (1.0) <0.001    1.1 (0.4)    1.9 (0.8) <0.001
Systolic blood pressure, mm Hg 144.7 (19.2) 147.5 (18.0)   0.090  148.9 (21.0)  153.9 (20.9)   0.007 
Diastolic blood pressure, mm Hg  83.9 (9.2)  85.1 (9.8)   0.166  81.6 (8.7)  84.6 (9.8) <0.001
IFG/ IGT/ type 2 diabetes, % 12 / 9 / 8 20 / 16 / 38 <0.001 4 / 9 / 3 15 / 17 / 28 <0.001
Cardiovascular disease, % 25 32   0.052 17 21   0.328 
Lipid lowering medication, % 33 41   0.046 31 44   0.003 
Antihypertensive medication, % 35 57 <0.001 33 69 <0.001
Metabolic risk factors, no.    1.3 (0.6)    3.5 (0.7) <0.001    1.3 (0.7)    3.5 (0.7) <0.001
Data are presented as means (± SD) or percentages (%). P-values for difference between groups are from 
independent-samples t-test, Mann-Whitney or Ȥ2-test as appropriate. For glucose and triglycerides P-values were 
derived from log-transformed values. Body mass index was calculated as weight (kg) divided by height (m) squared. 
IFG; impaired fasting glucose, IGT; impaired glucose tolerance.  
59
The prevalence of metabolic syndrome (Figure 7) and IGR (Figure 8) were higher in 
men and women in the two lowest thirds of VO2max than in those in the highest third.
Figure 7. Prevalence (%) of metabolic syndrome across sex-specific VO2max
thirds (ml·kg-1·min-1). P-value from Ȥ2 test.
Figure 8. Prevalence (%) of impaired glucose regulation in non-diabetic men and 
women across sex-specific VO2max thirds (ml·kg
-1·min-1). P-value from Ȥ2 test.
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As a continuous variable, a decrease of 1 SD in VO2max in men (6.3 ml·kg
-1·min-1) and 
women (4.9 ml·kg-1·min-1) was associated with a 3.2-fold (95% CI 2.45-4.10, P<0.001) 
and 3.1-fold (2.39-4.00, P<0.001) increase in the risk of having the metabolic syndrome 
after adjustment for age, smoking, alcohol consumption and CVD. Further adjustment 
for waist circumference [OR (95% CI) in men: 1.5 (1.09-2.03), P=0.012; women: 1.4 
(1.00-1.90), P=0.053] and body mass index [men: 1.8 (1.31-2.36), P<0.001; women: 1.5 
(1.12-2.07), P=0.008] weakened the association. Of other metabolic risk factors, the 
next strongest confounder after waist circumference was HDL cholesterol [2.4 (1.84-
3.16), P<0.001] and triglycerides [2.6 (1.95-3.45), P<0.001] in men and glucose [2.7 
(1.99-3.61), P<0.001] and triglycerides [2.7 (1.96-3.69), P<0.001] in women. When 
VO2max was expressed as L·min
-1, a 1-SD decrease in VO2max was associated with a 1.8-
fold (1.37-2.31, P<0.001) increase in the risk of having metabolic syndrome in men and 
a 1.4-fold (1.10-1.87, P=0.007) increase in women adjusted for age, smoking, alcohol 
consumption, CVD and body weight. 
VO2max in sex-specific thirds was associated with all of the components of the metabolic 
syndrome (Table 10). 
Table 10. Components of metabolic syndrome according to sex-specific thirds of maximal oxygen uptake  
Thirds in men (ml·kg-1·min-1)
  low     medium      high 
Thirds in women (ml·kg-1·min-1)
 low      medium     high 
<23.3   23.3-29.1  >29.1          P         <18.4    18.4-22.8  >22.8         P 
Waist circumference, cm 107.2   98.7   90.9 <0.001   96.9   89.1   79.8 <0.001 
Body mass index   30.5   27.4   25.2 <0.001    30.7   27.6   24.3 <0.001 
Fasting glucose, mmol/l    6.3    5.9    5.8 <0.001    5.9    5.6    5.4 <0.001 
Triglycerides, mmol/l    1.7    1.4    1.2 <0.001    1.5    1.4    1.1 <0.001 
HDL cholesterol, mmol/l    1.4    1.5    1.7 <0.001    1.7    1.8    2.0 <0.001 
Systolic blood pressure,  
mm Hg 
148.0 145.8 142.7   0.027 153.0 151.0 146.4   0.005 
Diastolic blood pressure,  
mm Hg 
 85.6  84.3  82.8   0.015  83.6   83.2  80.3 <0.001 
Data are presented as means. P for difference between groups from analysis of covariance. For glucose 
and triglycerides P-values were derived from log-transformed values. Body mass index was calculated as 
weight (kg) divided by height (m) squared.  
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In both men and women, VO2max had a strong, inverse and graded association with the 
risk of having the metabolic syndrome (Figure 9, P<0.001 for linear trend). Men and 
women in the lowest third of VO2max had a 10.2 and 10.8-fold higher risk and those in 
the middle third had a 2.9 and 4.7-fold higher risk of the metabolic syndrome than those 
in the highest third, adjusted for age, smoking, alcohol consumption and CVD. 
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Figure 9. Odds of having metabolic syndrome in sex-specific thirds of VO2max (ml·kg
-1·min-1)
adjusted for age, alcohol consumption and CVD. P for difference between groups. 
The prevalence of the metabolic syndrome in men <61, 61-65, 66-70, and >70 years of 
age was 31%, 27%, 27%, and 25%, respectively. In women, these rates were 24%, 29%, 
23%, and 23%. The association between VO2max and metabolic syndrome seemed to be 
stronger in men >70 years of age than in other men (Table 11).  
Table 11. The risk of the metabolic syndrome for a 1-SD decrease in VO2max (6.3 ml·kg
-1·min-1
in men and 4.9 ml·kg-1·min-1 in women) in 5-year age categories. 
MEN WOMEN
Age Odds ratio 95% CI P Odds ratio 95% CI P
       <61 year 3.0 1.81-5.13 <0.001 4.5 2.31-8.70 <0.001
    61-65 year 2.6 1.60-4.08 <0.001 2.4 1.61-3.68 <0.001
    66-70 year 3.0 1.90-4.90 <0.001 2.9 1.73-4.95 <0.001
       >70 year 6.3  3.07-13.16 <0.001 3.8 2.14-6.85 <0.001
From logistic regression analysis. Adjusted for smoking, alcohol and CVD.
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In men and women without diabetes, there was an inverse association between VO2max
and the risk of having IGR. A 1-standard deviation decrease in VO2max was associated 
with a 1.4-fold (95% CI 1.15-1.78, P=0.001) increase in the risk of having IGR in men 
and with a 1.6-fold (1.25-2.08, P<0.001) increase in the risk in women, adjusted for age, 
smoking, alcohol consumption and CVD. Men and women in the lowest third of VO2max
had a 2.4-fold increased risk of IGR compared with the highest third of VO2max (Figure 
10, P=0.001 in men and P=0.002 in women for trend across the thirds).  
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Figure 10. Odds of having impaired glucose regulation in sex-specific thirds of VO2max (ml· 
kg-1·min-1), adjusted for age, alcohol consumption and CVD. P for difference between groups. 
In the factor analysis containing core components of the metabolic syndrome, 
cardiorespiratory fitness, smoking and alcohol consumption, four factors with 
eigenvalues >1 were extracted and rotated using the promax method. These factors 
explained 62% of the total variance in men and women. Factor loadings of the variables 
with each factor are shown in Table 12. The factor explaining the greatest proportion of 
the total variance (29% in men and 30% in women) had heavy loadings on the core 
components of the metabolic syndrome and VO2max. The second strongest factor had 
heavy loadings on triglycerides, LDL cholesterol and HDL cholesterol in both men and 
women. 
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Table 12. Loadings of 12 variables related to metabolic syndrome on the four factors extracted and  
rotated (promax) with factor analysis and the variance explained by each factor 
MEN WOMEN 
Factor 1 2 3 4 1 2 3 4
Proportion of variance, % 29 12 11 10 30 12 10 10
Waist girth  0.79  0.19  0.19  0.003  0.93 -0.07 -0.10  0.11 
Body mass index  0.78  0.20  0.14  0.04  0.93 -0.12 -0.04  0.10 
Fasting plasma glucose  0.75 -0.17  0.03  0.23  0.64  0.01  0.18  0.05 
2-hour glucose load  0.68 -0.09 -0.09  0.40  0.57  0.07  0.38 -0.03 
Serum triglycerides  0.25  0.67 -0.02 -0.04  0.28  0.58 -0.08 -0.19 
Serum HDL cholesterol -0.28 -0.50  0.39  0.23 -0.30 -0.39  0.22  0.33 
Serum LDL cholesterol -0.40  0.79  0.18  0.28 -0.31  0.91  0.15  0.21 
Systolic blood pressure  0.28  0.07 -0.05  0.84  0.26  0.15  0.65  0.21 
Maximal oxygen uptake -0.68  0.05  0.05  0.07 -0.70  0.03 -0.11  0.02 
Alcohol consumption  0.09  0.04  0.85  0.03  0.14  0.06 -0.10  0.88 
Smoking  0.17 -0.05  0.59 -0.44  0.04  0.09 -0.71  0.41 
5.3 High-sensitivity C-reactive protein and the metabolic syndrome (Study II) 
At baseline, the hsCRP concentrations increased significantly with increasing number of 
components of the metabolic syndrome (Figure 11). The mean hsCRP was twice as high 
in women with the metabolic syndrome as in those without it (3.1 vs. 1.5 mg/l). 
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Figure 11. High-sensitivity C-reactive protein (hsCRP) concentrations in women with 0, 1, 2 or 
3 components of the metabolic syndrome at baseline.
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Whereas hsCRP concentration increased markedly in 37 women who developed the 
metabolic syndrome during 12 years, it did not change in those 55 women who 
remained free of it or in those 11 with the metabolic syndrome already at baseline
(Figure 12). 
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Figure 12. High-sensitivity C-reactive protein (hsCRP) at baseline (1992) and after 12-year 
follow-up (2003) in women with no metabolic syndrome during the study, incident metabolic 
syndrome or metabolic syndrome already at the baseline and after the 12 years. 
Women with incident metabolic syndrome had higher waist circumference (87.8 vs. 
77.4 cm), body weight (71.2 vs. 62.7 kg), and body mass index (28.8 vs. 25.4) at 
baseline than those who did not develop the metabolic syndrome (P<0.001 all). 
An increment of 1 mg/l in hsCRP concentration during 12 years was associated with 
a 37% (P=0.007) increase in the risk of developing the metabolic syndrome after 
adjustment for age, smoking, the use of drugs for hypercholesterolemia, hormone 
replacement therapy, and prevalent CVD. A 1 mg/l increment in hsCRP was associated 
with a 26% (P=0.047) increase in the risk after further adjustment for change in waist 
circumference and with a 31% (P=0.018) increase after additional adjustment for 
change in triglycerides. Adjustment for changes in other components of metabolic 
syndrome had no effect on the association.  
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In women for whom hsCRP decreased, increased by 0-1 mg/l, or increased by >1 
mg/l in 12 years, the metabolic syndrome developed in 22, 50, and 60%, respectively, 
during 12 years (P=0.005 for difference). Compared with women for whom hsCRP 
decreased, those with an increment in hsCRP of 0-1 mg/l had a 4.5-fold higher 
(P=0.011) and those with hsCRP increase of >1 mg/l had a 6.2-fold higher (P=0.002) 
risk of developing the metabolic syndrome after adjustment for baseline age, smoking, 
the use of drugs for hypercholesterolemia, hormone replacement therapy, and prevalent 
CVD (Table 13, Model 1). The association of hsCRP change with the risk of developing 
the metabolic syndrome was weakened after further adjustment for change in waist 
circumference or triglycerides, but changes in other components of the metabolic 
syndrome did not materially affect the association (Table 13, Models 2-6). 
Table 13. Odd ratios (95% CI) for developing the metabolic syndrome during 12 years of 
follow-up in women without the metabolic syndrome at baseline stratified according to changes 
in high-sensitivity C-reactive protein (hsCRP) levels during 12 years of follow-up 
hsCRP change <0 mg/l 0-1 mg/l >1 mg/l P for trend 
n 41 26 25
Model 1 1 4.5 (1.4-14.3) 6.2 (1.9-19.9) 0.002 
Model 2 1      2.7 (0.8-9.3) 4.4 (1.3-15.0) 0.018 
Model 3 1 3.7 (1.1-12.3) 4.7 (1.4-15.6) 0.010 
Model 4 1 3.9 (1.2-12.9) 5.8 (1.8-19.0) 0.003 
Model 5 1 6.1 (1.6-23.8) 8.2 (2.2-31.5) 0.002 
Model 6 1 5.2 (1.6-17.4) 7.5 (2.2-25.6) 0.001 
From logistic regression analysis. Adjustments in Models 1-6: 
Model 1: age, smoking, drugs for hypercholesterolemia, hormonal therapy, and CVD at baseline 
Model 2: variables in Model 1 and change in waist circumference during follow-up 
Model 3: variables in Model 1 and change in triglycerides during follow-up 
Model 4: variables in Model 1 and change in HDL cholesterol during follow-up 
Model 5: variables in Model 1 and change in blood glucose during follow-up 
Model 6: variables in Model 1 and change in systolic blood pressure during follow-up 
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5.4 Waist and hip circumference and carotid atherosclerosis (Study III)
At baseline, waist circumference (in thirds; <77, 77-86, >86 cm) was directly associated 
with body weight (58.4, 65.8 and 77.8 kg), body mass index (23.4, 26.6, 31.2), hip 
circumference (89.3, 98.8 and 108.8 cm), triglycerides (1.0, 1.3 and 1.4 mmol/l) (in all, 
difference between groups P<0.001), and systolic blood pressure (150.5, 152.7 and 
163.0 mm Hg, P=0.04) and inversely with HDL cholesterol (1.7, 1.6 and 1.5 mmol/l, 
P=0.02). Hip circumference (in thirds; <94, 94-101.5, >101.5 cm) was directly related 
to body weight (58.6, 66.4 and 77.8 kg), body mass index (23.4, 26.8, 31.4), waist 
circumference (73.6, 82.2 and 92.5 cm) (in all, difference between groups P<0.001), 
triglycerides (1.0, 1.3 and 1.3 mmol/l, P=0.04), hsCRP (0.9, 1.2 and 2.1 mg/l, P=0.01) 
and systolic (144.5, 157.8 and 164.4 mmol/l, P<0.001), and diastolic (85.8, 88.8 and 
91.5 mm Hg, P=0.07) blood pressure and inversely to HDL cholesterol (1.7, 1.5 and 1.6 
mmol/l, P=0.005). 
There was a significant increase in the 12-year carotid IMT progression between the 
thirds of waist circumference after adjustment for conventional risk factors, including 
age, smoking, systolic blood pressure, serum LDL and HDL cholesterol, and blood 
glucose (Table 14). The association was not significant after further adjustment for hip
circumference or body mass index (Table 14) or triglycerides (0.110, 0.272 and 0.249 
mm, P=0.11). Although additional adjustment for hsCRP, family history of CHD and 
physical activity at baseline and the 12-year change in the amount of physical activity 
had no effect on the association (data not shown), adjustment for 12-year changes in 
LDL and HDL cholesterol, blood glucose and hsCRP weakened it slightly (0.093, 0.278 
and, 0.260 mm, P= 0.06). 
The progression in carotid IMT over12 years also increased across the thirds of hip 
circumference adjusted for conventional risk factors (Table 14). Further adjustment for 
waist circumference or body mass index had no effect on the association (Table 14). 
Adjustment for triglycerides, hsCRP, family history of CHD, physical activity at 
baseline or 12-year changes in LDL and HDL cholesterol, blood glucose, hsCRP and 
the amount of physical activity did not change the association either (data not shown). 
The difference in the 12-year carotid IMT progression among the body mass index 
groups (<25, 25-30, >30) was significant after adjustment for conventional risk factors 
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(Table 14), but no longer after further adjustment for waist or hip circumference (Table 
14) or triglycerides (0.112, 0.272 and 0.263 mm, P=0.07). Adjustment for hsCRP, 
family history of CHD, and physical activity at baseline and 12-year change in the 
amount of physical activity did not affect the association (data not shown), whereas 
adjustment for 12-year changes in LDL and HDL cholesterol, blood glucose, and 
hsCRP weakened it slightly (0.107, 0.278 and 0.260 mm, P= 0.07). The association 
between thirds of the waist-to-hip ratio and carotid IMT progression was not significant 
(data not shown).
 
Table 14. Increase in carotid intima-media thickness (IMT) at the 12-year follow-up. Waist and 
hip circumferences were categorized into thirds and body mass index according to generally 
used clinical cut-off points 
Increase in IMT, mean (95% CI)
Waist circumference 
<77 cm (n=33) 0.080 (-0.032-0.193)a 0.109 (-0.040-0.254)b 0.090 (-0.054-0.235)d
77-86 cm (n=35) 0.277 (0.170-0.383)a 0.281 (0.173-0.389)b 0.278 (0.171-0.385)d
>86 cm (n=34) 0.279 (0.166-0.391)a 0.241 (0.090-0.406)b 0.262 (0.113-0.411)d
P-value for difference 0.02a 0.15b 0.11d
Hip circumference 
<94 cm (n=34) 0.030 (-0.079-0.140)a 0.063 (-0.079-0.205)c 0.037 (-0.106-0.180)d
94-101.5 cm (n=36) 0.342 (0.240-0.444)a 0.345 (0.243-0.448)c 0.342 (0.239-0.445)d
>101.5 cm (n=32) 0.260 (0.151-0.368)a 0.221 (0.068-0.374)c 0.251 (0.098-0.405)d
P-value for difference 0.001a 0.004c 0.003d
Body mass index 
<25 (n=37) 0.095 (-0.009-0.200)a 0.130 (-0.008-0.268)c 0.124 (-0.008-0.256)b
25 - 30  (n=43) 0.281 (0.185-0.377)a 0.279 (0.182-0.375)c 0.280 (0.183-0.376)b
>30       (n=22) 0.274 (0.140-0.408)a 0.220 (0.025-0.414)c 0.229 (0.043-0.414)b
P-value for difference 0.03a 0.19c 0.16b
From analysis of covariance. Body mass index was calculated as weight divided by height squared. 
a Adjusted for age, smoking, systolic blood pressure, LDL and HDL cholesterol, and blood glucose  
b Adjusted for model a and hip circumference 
c Adjusted for model a and waist circumference
d Adjusted for model a and body mass index 
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In women with hip circumference 98 cm, the progression in carotid IMT over 12 years 
was significantly greater in those with waist circumference >83 cm than in those with a 
smaller waist circumference after adjustment for conventional risk factors (Figure 13, 
P=0.003 for interaction). Additional adjustment for body mass index, triglycerides, 
hsCRP, family history of CHD, physical activity at baseline or 12-year changes in LDL 
and HDL cholesterol, blood glucose, hsCRP and amount of physical activity had no 
effect on the difference (data not shown). In women with waist circumference >83 cm, 
there was a significant difference in carotid IMT progression between those with hip 
circumference >98 cm and those with lower hip circumference (Figure 13). This 
difference was not affected by additional adjustments. In women with hip circumference 
>98 cm, there was no significant difference in carotid IMT progression between women 
with waist circumference higher or lower than 83 cm (Figure 13).  
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Figure 13. Increase in carotid intima-media thickness (IMT) according to baseline waist and hip 
circumference adjusted for age, smoking, systolic blood pressure, LDL and HDL cholesterol, 
and blood glucose. Waist and hip circumferences were dichotomized at the mean. 
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5.5 Metabolic syndrome and carotid atherosclerosis (Study IV) 
At baseline, women with metabolic syndrome had an 18% greater mean carotid IMT 
than those without metabolic syndrome (1.21 vs. 1.03 mm, P=0.06). There was no 
difference in the change of carotid IMT during 12 years between 88 women without the 
metabolic syndrome at baseline and 13 women with it (+0.21 vs. +0.20 mm, P=0.92). 
After the 13 women with metabolic syndrome already at baseline were excluded, 34 
women who developed the metabolic syndrome during the 12 year follow-up had higher 
waist circumference (88.2 vs. 76.3 cm, P<0.001) and body mass index (29.1 vs. 25.0, 
P<0.001) at baseline than the 54 women without the metabolic syndrome after the 12 
year follow-up. The mean increase in the mean carotid IMT was 2.0 times greater in 
those women who developed the metabolic syndrome than in those who did not after 
adjustment for age, CVD, physical activity, smoking, alcohol, LDL cholesterol, lipid 
lowering medication, carotid IMT, and metabolic risk score at baseline (Figure 14). 
Further adjustment for waist circumference at baseline reduced the difference in the 
carotid IMT progression by 23% (P=0.19) and adjustment for triglycerides by 19% 
(P=0.10). The difference remained significant after further adjustment for glucose, HDL 
cholesterol, systolic blood pressure, or Framingham risk score at baseline or change in 
the amount of physical activity during the follow-up. 
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Figure 14. The change in carotid intima-media thickness (IMT) according to incident metabolic 
syndrome during the 12-years, after excluding women with the metabolic syndrome at baseline 
adjusted for age, CVD, physical activity, smoking, alcohol, LDL cholesterol, lipid lowering 
medication, carotid IMT, and metabolic risk score in 1992. 
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In the 88 women without the metabolic syndrome at baseline, the development of 
more metabolic risk factors during the 12-year follow-up was associated with a greater 
increase in the mean carotid IMT (Figure 15). The carotid IMT increase was 2.4 times 
greater in women who developed at least two metabolic risk factors than in those with 
no increase in risk factors after adjustment for age, prevalent CVD, physical activity, 
smoking, alcohol, LDL cholesterol, lipid lowering medication, carotid IMT and 
metabolic risk score at baseline. Adjustment for waist circumference at baseline reduced 
the difference in the carotid IMT increase by 21% (P=0.10) and triglycerides by 20% 
(P=0.13). Again, adjustment for glucose, HDL cholesterol, systolic blood pressure, or 
the Framingham risk score at baseline or change in amount of physical activity during 
the follow-up had no effect on the difference. 
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Figure 15. The change in carotid intima-media thickness (IMT) according to the increasing 
number of metabolic risk factors during the 12-year follow-up, after excluding women with the 
metabolic syndrome at baseline, adjusted for age, CVD, physical activity, smoking, alcohol, 
serum LDL cholesterol, lipid lowering medication, carotid IMT and metabolic risk score in 
1992.  
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Of risk factors for the progression of carotid IMT, including baseline carotid IMT, 
age, triglycerides, LDL cholesterol, HDL cholesterol, glucose, waist circumference and 
systolic blood pressure, only baseline carotid IMT (ȕ=-0.295, P=0.003), age (ȕ=0.196,
P=0.05), triglycerides (ȕ=0.248, P=0.01) and waist circumference (ȕ=0.220, P=0.03) 
were associated with the change in carotid IMT over 12 years in unadjusted linear 
regression analyses. When all risk factors were entered simultaneously into the model, 
only baseline carotid IMT (ȕ=-0.302, P=0.003) and age (ȕ=0.193, P=0.05) were 
independently associated with the change in carotid IMT. 
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6. DISCUSSION 
 
6.1 Summary of the main findings 
The purpose of the present thesis was to extend knowledge on the predictors and 
consequences of the metabolic syndrome in aging men and women.  
 Cardiorespiratory fitness had a strong, inverse, graded and independent association 
with the metabolic syndrome in older men and women. Individuals in the lowest third of 
VO2max had a 10 times higher risk and those in the middle third had 3 to 5 times higher 
risk of having the metabolic syndrome than those in the highest third of VO2max. Low 
cardiorespiratory fitness was also associated with IGR in men and women without 
diabetes, but the relationship was weaker than that for the metabolic syndrome. 
 Even a slight increment (<1 mg/l) in the serum level of high-sensitivity CRP was 
associated with 4 to 6 times higher risk of developing the metabolic syndrome during 12 
years of follow-up in elderly women. The relationship was independent of abdominal 
obesity and other components of the metabolic syndrome. 
 The progression of preclinical carotid atherosclerosis during 12 years was greater 
among elderly women in the two highest thirds of waist and hip circumferences and in 
women with overweight than in other women. Women with both a larger waist 
circumference and a smaller hip circumference had the greatest progression of carotid 
IMT.
 Incident metabolic syndrome and an increasing number of metabolic risk factors 
predicted the progression of preclinical carotid atherosclerosis during 12 years in elderly 
women. The mean increase in the carotid IMT was two times greater in women who 
developed the metabolic syndrome than in those who did not. The metabolic syndrome 
was a stronger predictor of carotid atherosclerosis progression than the individual 
components of the syndrome. 
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6.2 Methodological aspects
6.2.1 Study populations and design
In Study I, the baseline data of the ongoing randomized controlled trial, the DR’s 
EXTRA Study, were used. The study population was a representative sample (nearly 
20%) of 55 to 57 year old men and women from the city of Kuopio, Eastern Finland. 
About two thirds of the invited subjects were initially willing to participate in the study 
(Figure 4). About three fourths of them finally participated in the baseline examinations. 
Because of the age range and the relatively long run-in period, it is understandable that 
some of those who had expressed their willingness to the study were not able to 
participate due to different reasons (10% lack of motivation, 8% illness, 3% relocation, 
2% death). This large study makes it possible to investigate the association of 
cardiorespiratory fitness with IGR and the metabolic syndrome in older men and 
women. Few studies of this topic are available in representative population samples of 
both men and women, especially in older individuals (Table 3). Because the baseline 
data of the ongoing study was available in the present study we had a cross-sectional 
study design, which limits deductions about causality and its direction. However, the 
notable strengths of the study are the representative population-based random sample, 
inclusion of both men and women, and focus on older age groups.  
Studies II-IV consisted of a randomly selected population-based cohort of elderly 
women with a long follow-up period (Figure 5). Most previous studies of the 
associations of the variables of interest have included middle-aged individuals or have 
not specifically studied elderly individuals, especially women (Tables 2, 4, 5). Follow-
up data are also scarce. The present data of this follow-up study are well-timed and 
important because women, especially elderly, have been underrepresented in 
epidemiological studies and represent a growing segment of the population. The study 
design provided an opportunity to investigate the predictive value of metabolic and 
cardiovascular risk factors in relation to the metabolic syndrome and preclinical carotid 
atherosclerosis in elderly women. Due to the long follow-up in older women, many of 
whom died or developed chronic diseases, the number of subjects in the 12-year follow-
up visit was markedly reduced. Further, some subjects could not participate in the 
follow-up visits due to a long distance from home to the research institute and 
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transportation problems. Given these limitations, the participation rate can be 
considered fairly good. However, the relatively small study sample limits the statistical 
power and may lead to the underestimation of the true associations. A considerable 
increase in the use of antihypertensive and lipid lowering medications apparently 
decreased blood pressure and cholesterol during the 12 years. Also, a selection bias of 
healthier and slightly younger women in the follow-up complicates the generalization of 
the results to entire population. This may also lead to underestimation of the true 
associations, because of smaller differences in the variables of interest in population 
extremes.  
6.2.2 Definition of the metabolic syndrome 
The NCEP definition of the metabolic syndrome is simple to use in large 
epidemiological and intervention studies and in clinical practice. It has been one of the 
most widely used definitions during recent years, which helps in comparing the results 
with other studies. In contrast, the WHO definition requires clinical evidence of 
impaired glucose status, insulin resistance or diabetes mellitus in addition to two or 
more other risk factors, including microalbuminuria, which complicates its use in 
epidemiological studies and clinical practice. The latest definition, IDF, requires the 
presence of abdominal obesity, and the thresholds for abdominal obesity and impaired 
fasting glycemia are much lower than in the original NCEP definition. It is thus not 
surprising that IDF criteria classify a larger population as having metabolic syndrome 
than the NCEP.  
 Although the components of the metabolic syndrome occur more commonly in 
overweight and obese individuals, as postulated in IDF definition, there are individuals 
who are obese, but otherwise metabolically normal and individuals with normal weight 
with insulin resistance and other features of the metabolic sydrome (66,70,72). By using 
IDF criteria individuals with all other components of the metabolic syndrome except 
abdominal obesity are not defined as having the metabolic syndrome. Such individuals 
nonetheless have the metabolic syndrome, and therefore have an increased risk of type 2 
diabteses and CVD. The NCEP definition considers central obesity as one of the five 
equally weighted criteria. A number of other metabolic and cardiovascular risk factors, 
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such as hsCRP, cytokines, fibrinogen, PAI-1, endothelial dysfunction, have been 
suggested as components of the metabolic syndrome (23,257). However, available data 
have not been sufficient to include them in the current definitions.  
Although the NCEP and WHO definitions differ in their criteria, both have been 
considered useful for predicting diabetes, CVD and mortality (14,27,215,258-260). In 
contrast, evidence for the role of IDF definition in predicting these outcomes is limited 
(260). In a recent population-based study, the prevalence of the metabolic syndrome 
according to the IDF criteria was significantly higher than that according to the NCEP 
or WHO criteria, and the subjects identified in excess using the IDF criteria were less 
insulin resistant and have less carotid atherosclerosis (213). Inconsistent results exist of 
the current definitions regarding the ability to best predict diabetes and CVD. In Finnish 
men, the WHO definition seemed to predict CVD better than the NCEP (258). In 
another study, both definitions were predictive in a general population, but the NCEP 
was more predictive in lower-risk subjects (259). In a recent study, WHO, NCEP and 
IDF have a similar ability, even though different sensitivity, to predict incident diabetes 
and CVD (260). The sensitivity, but also the false positive rate, was somewhat higher 
by IDF definition. It is still under research whether the metabolic syndrome is a useful 
marker of CVD risk above and beyond the risk associated with its individual 
components. In general, the differences in the criteria of the metabolic syndrome 
definitions, including differences in the cut-offs of components and the way in which 
the components are combined, complicate comparability between studies. 
We used the NCEP definition for the metabolic syndrome, because it is widely used 
in research and clinical practice, is useful in predicting type 2 diabetes, CVD and 
mortality, all variables needed were available, and the IDF criteria were only recently 
published.
6.2.3 Assessment of obesity 
Overall obesity was assessed using the body mass index. Waist and hip circumferences 
were used to assess the distribution of body adiposity. Trained nurses carried out all the 
anthropometric measurements following a standard protocol. Waist and hip 
circumferences were measured twice, and the mean was used in the analyses. The 
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location of the measurement was selected carefully to increase precision. There are 
variations between studies in the site of especially waist circumference measurement, 
which complicates comparability. In some studies, waist circumference has been 
measured at the level of umbilicus, which may cause false estimates compared with 
measurement at a well-defined area between the rib cage and the iliac crest. The 
weakness of the current metabolic syndrome definitions is that they do not have 
instructions for waist and hip circumference measurements. In the present study, high 
intraclass correlations and small coefficient of variations (see 4.2) show a high 
reliability and repeatability between two consecutive measurements of waist and hip 
circumferences. 
Waist circumference reflects mainly variation in subcutaneous and visceral fat, 
whereas hip circumference is also associated with bone structure in the pelvis, muscle 
mass in gluteo-femoral region, and subcutaneous fat mass (55). Compared with middle-
aged individuals, hip circumference may reflect fat mass more than muscle mass in the 
elderly because of age-associated decrease in muscle mass. Body mass index provides a 
broad, nonspecific estimate of obesity, is easily obtained and commonly used in clinical 
practice. A potential limitation of body mass index measurement is that it does not take 
into account body fat distribution. For an equivalent body mass index, women have 
significantly greater amounts of total body fat than men do (261). Body mass index may 
not be the most appropriate measure of body composition in the elderly, in whom body 
height diminishes gradually after middle-age due to posture changes and osteoporosis, 
and lean body mass declines because of sarcopenia. Thus, in the elderly, the body mass 
index value may be in the normal-weight range despite muscle loss and excess body fat. 
Further, there are ethnic differences in the relations between various body mass index 
values and the risk of CVD (29). There is relative consensus about the classification for 
general adiposity based on WHO recommendations of body mass index (29). There is 
less consistency in the selection and cut-off points for indicators of abdominal obesity 
(262). Because each measure of body composition has its strengths and limitations, 
simultaneous assessment of waist and hip circumferences is reasonable in studies, 
especially among older individuals. 
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6.2.4 Assessment of cardiorespiratory fitness 
Cardiorespiratory fitness is an objective measure of recent physical activity. It is 
stronger than self-reported physical activity as a predictor of many health outcomes, at 
least in part because fitness measurements are less prone to misclassification than self-
reported physical activity (263). VO2max can be measured directly or estimated from the 
treadmill or cycle ergometer work load or exercise time. In the present study, VO2max
was assessed directly using a respiratory gas exchange analysis during a symptom-
limited maximal cycle ergometer test, which is an accurate and highly reproducible 
measure of cardiorespiratory fitness (123,264). Although VO2max is measured in liters 
per minute, it is commonly expressed as milliliters of oxygen per kilogram of body 
weight per minute to facilitate comparison of values among individuals of different 
body size.
There are different protocols in use with different magnitude of increments in work 
rate. We used a standardized test protocol with a warm-up of 3 minutes at 20 W and a 
20 W-increase in the workload per minute. Predicting VO2max from the treadmill or 
cycle ergometer work load is common clinically. This can be misleading especially in 
persons with heart disease, because the protocol will overpredict their exercise capacity 
(120). Inaccuracy occurs also if the subject does not have treadmill experience or is 
untrained.  Because joint and balance disorders are common in older individuals, the 
cycle ergometer test may be a better choice than walking on the treadmill, which 
requires weight-bearing and balance. On the other hand, directly measured VO2max is
time-consuming, expensive, requires specialized equipment and considerable physical 
effort and motivation. Thus it is rarely used in large studies and is not considered very 
suitable for clinical practice. However, as the present study showed, directly measured 
VO2max is a suitable test even for the older population. Even though the oldest 
individuals were almost 80 years, the tests were carried out without serious problems. 
6.2.5 Assessment of low-grade inflammation 
CRP is currently considered to be the most reliable and widely available inflammatory 
marker for clinical use (265). In the present study, CRP was measured with a high-
sensitivity assay, in which case CRP levels are considered to have a long-term 
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predictive value (146). hsCRP concentrations <1, 1-3, and >3 mg/l refer to low, 
moderate and high cardiovascular risk (265). We used an immunoassay system that is 
capable of detecting very low concentrations of CRP, starting from 0.1 mg/l. In contrast, 
the measurement range for many clinically used and less expensive CRP starts from 1 
mg/l. Intraclass correlations and coefficients of variation in baseline and after follow-up 
show a high reliability of hsCRP measurements (see 4.5). Baseline serum samples were 
stored at -80ºC during 12 years which can be considered the best available way to 
ensure the quality of the stored samples. Because baseline and follow-up samples were 
analyzed at the same time and with the same method, potential measurement errors that 
may occur due to changes in analysis methods over time are decreased. 
6.2.6 Assessment of carotid atherosclerosis 
High-resolution B-mode ultrasonography together with automated analyzing software 
was used to detect early changes in the arterial intima-media layer of the carotid 
bifurcation (254). Three certified sonographers performed the ultrasound scannings in 
both study years with the same ultrasound device, following a standardized and 
pretested protocol. IMT was measured at the carotid bifurcation, because area is prone 
to plaque formation (199) and is considered the best site along the carotid tree for use as 
a marker of atherosclerosis (266). Although there is also some disagreement as to what 
is the best site of the carotid tree as a marker of atherosclerosis (267) or as to whether 
carotid IMT is a surrogate marker of coronary atherosclerosis (268), carotid IMT is 
widely considered to be a useful measure of preclinical atherosclerosis.  
 Carotid IMT reflects generalized atherosclerosis (266), and an increase in carotid 
IMT has been validated as a vascular marker of the progression of preclinical 
atherosclerosis (202). However, carotid IMT is not synonymous with atherosclerosis, 
but is rather a marker of hypertrophy of intima and media layers of the artery wall 
(266). Carotid ultrasonography is a more suitable technique for assessing the 
progression of preclinical atherosclerosis than the quantification of coronary calcium, 
especially in the elderly, most of whom have coronary calcification. High-resolution 
magnetic resonance imaging is another non-invasive method for imaging 
atherosclerosis, but the prognostic value of cardiovascular magnetic resonance needs 
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more evidence (269). Angiography is used clinically for detecting coronary 
atherosclerosis. However, early atherosclerosis can not be reliable detected using 
angiography (202).
 As a noninvasive measure, carotid IMT is a safer and cost effective method for 
assessing preclinical atherosclerosis than angiography (202). The present study is one of 
the few population-based long-term studies of the association of metabolic syndrome 
with carotid IMT from which data on the progression of carotid IMT are available. 
6.3 Results  
6.3.1 Cardiorespiratory fitness and the metabolic syndrome 
The main finding of this study in older men and women was a strong, inverse, graded 
and independent association of cardiorespiratory fitness with the risk of having the 
metabolic syndrome. The present results support the findings of cross-sectional and 
prospective studies concerning the association of cardiorespiratory fitness with 
metabolic syndrome (Table 3). Low cardiorespiratory fitness was also associated with 
impaired glucose homeostasis in non-diabetic men and women, but the relationship was 
weaker than that with the metabolic syndrome. Findings from factor analysis suggest 
that low cardiorespiratory fitness could be considered a component of metabolic 
syndrome, which confirms an earlier study in middle-aged men from the same area in 
Eastern Finland (132). 
The weakness of the most previous studies on the association of cardiorespiratory 
fitness with the metabolic syndrome (Table 3) is that the subjects were not individuals 
randomly selected from a general population. Only a few population-based studies have 
been published. Most have included only young and middle-aged individuals or men. 
Further, directly measured VO2max was not used as a measure of cardiorespiratory 
fitness, but instead was estimated based on duration of the treadmill time or using a 
submaximal test. In two studies in which cardiorespiratory fitness was only weakly 
associated with the metabolic syndrome or its development, VO2max was estimated with 
a submaximal exercise test (139,140).  
Of the single components of the metabolic syndrome, waist circumference markedly 
weakened the association between cardiorespiratory fitness and metabolic syndrome. 
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Abdominal obesity is closely related to cardiorespiratory fitness and is a core 
component of the metabolic syndrome. This is likely in part because a sedentary 
lifestyle predisposes to weight gain and increases central fat accumulation (127). Body 
mass index attenuated the association of VO2max with the metabolic syndrome less 
than waist circumference, which further suggests that waist circumference is a more 
useful measure of fat accumulation in the assessment of metabolic syndrome. Also, as 
discussed earlier (see 6.2.3) body mass index may not be the most appropriate measure 
of body composition in the elderly. In a recent study, the poor metabolic risk profile of 
middle-aged men with low cardiorespiratory fitness was associated with more visceral 
adipose tissue accumulation, defined by computed tomography, even after controlling 
for body mass index (270). 
One fourth of men and women had the metabolic syndrome. The rate is somewhat 
lower than comparatively aged men and women previously in Finland (3,6) and United 
States (4). The prevalence did not differ in the 5-year age categories. Also, the 
association of cardiorespiratory fitness with metabolic syndrome was materially similar 
in all 5-year age groups. The only exception was the group of men over 70 years, in 
which the association seemed to be stronger. 
Factor analysis reduces a large number of correlated variables to fewer factors that 
may explain or reflect complex underlying phenomena (271), such as in the metabolic 
syndrome (114,115,132). We found a principal metabolic syndrome factor that had 
heavy loadings by the main components of the metabolic syndrome and 
cardiorespiratory fitness. The loading was particularly high for waist circumference, 
which supports the central fat accumulation as a major component of the metabolic 
syndrome. Few previous studies have included cardiorespiratory fitness in the factor 
analyses with conventional metabolic risk factors (132).  
Lipids were included in more than one factor. LDL cholesterol is not considered a 
component of the metabolic syndrome, which may explain the small and negative 
loading in the principal factor and high positive loading on the second factor, which 
could be termed the lipid factor. The small negative loading of LDL cholesterol may 
also be in part because in the metabolic syndrome LDL cholesterol particle size is small. 
If the decrease in LDL particle size is greater than the increase in particle number, this 
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could be reflected in slightly lower LDL cholesterol concentrations, even though LDL 
concentrations have not been consistently associated with the metabolic syndrome. 
These findings suggest that while the metabolic syndrome may differ in its 
manifestations, there is still a common underlying pathophysiological process that 
explains the syndrome in most individuals. Abdominal obesity and poor 
cardiorespiratory fitness seem to be closely related to the underlying metabolic process. 
6.3.2 High-sensitivity C-reactive protein and the metabolic syndrome 
Inflammation plays a major role in the development of diabetes and CVD and is 
associated with several components of the metabolic syndrome, like obesity, insulin 
resistance, dyslipidemia, blood pressure, impaired fibrinolysis and endothelial 
dysfunction. The reason for a link between inflammation and the metabolic syndrome 
may be central adiposity. Abdominal obesity may increase cytokine release into the 
circulation, which in turn may increase the hepatic production of CRP (see 2.2.7). On 
the other hand, insulin resistance and aging are both associated with increased low-
grade inflammation. Some previous studies indicate that hsCRP might be a valuable 
addition to the definition of the metabolic syndrome to predict cardiovascular events 
(183,272), while other studies do not support this idea (173). 
Previous evidence of the association between elevated hsCRP levels and the 
metabolic syndrome derives mainly from cross-sectional studies, while only few 
prospective and population studies are available (Table 4). In an 11-year study, middle-
aged men with increased hsCRP levels were over three times more likely to develop the 
metabolic syndrome than those with low hsCRP levels (184). In a 6-year study, the 
association between hsCRP levels and the risk of developing the metabolic syndrome 
was present in middle-aged women, but not in men (182). 
The present 12-year follow-up study in elderly women provides new information 
because it shows that changes in hsCRP concentration are associated with the 
development of the metabolic syndrome. An important finding is that even a slight 
increment in hsCRP concentration in elderly women was associated with a 4 to 6 times 
higher risk for developing the metabolic syndrome than in those whose hsCRP 
concentration decreased during 12 years. The association held even after controlling for 
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abdominal obesity, a major correlate of serum hsCRP levels and crucial component of 
the metabolic syndrome. hsCRP was doubled in women who developed the metabolic 
syndrome during follow-up and reached the same level as in those who had the 
metabolic syndrome already at baseline. These findings are important, because even 
moderately elevated hsCRP concentration have been associated with an increased risk 
of future cardiovascular events among middle-aged women (148). 
In the present study, the direct association between hsCRP and the risk for the 
metabolic syndrome was partly explained by changes in waist circumference and 
triglycerides, major components of the metabolic syndrome. Adipose tissue may be 
partly responsible for a mild, chronic inflammatory state, which may induce insulin 
resistance. Furthermore, TNF-Į increases the serum concentration of triglycerides (see 
2.2.7). The aging-associated increase in fat mass and decrease in lean body mass may 
both accelerate the inflammatory process and development of the metabolic syndrome 
in the elderly. Moreover, in elderly women decreased estrogen levels have been 
associated with inflammation (170). It has also suggested that in women who are obese, 
but otherwise metabolically healthy with high insulin sensitivity, a lower inflammatory 
state could be associated with a lower risk of CVD (71). 
6.3.3 Waist and hip circumference and carotid atherosclerosis 
In the present study, the progression of carotid atherosclerosis during 12 years was 
greater among elderly women in two highest thirds of waist and hip circumferences and 
in women with overweight than in other women. Hip circumference was associated with 
the increase in carotid IMT independently of waist circumference and body mass index, 
while waist circumference and body mass index had no significant association with 
carotid IMT increase after taking into account other measures of body adiposity. A 
small hip circumference was related to carotid IMT progression in women with a large 
waist circumference, whereas waist circumference did not provide additional 
information in women with a large hip circumference. Our results agree with those from 
a previous cross-sectional study in which the prevalence of atherosclerotic disease was 
highest among individuals with a large waist circumference and a small hip 
circumference (273). 
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A number of previous studies have evaluated the relationship between obesity and 
CVD, but limited evidence exists for the association of different measures of body 
adiposity with preclinical atherosclerosis (Table 2), especially in the elderly. Few if any 
studies have assessed the association between hip circumference and atherosclerosis. In 
a 4-year follow-up study in middle-aged men, waist-to-hip ratio and waist 
circumference were associated with an accelerated increase in carotid IMT 
independently of body mass index, while body mass index had no independent 
association with the increase in carotid IMT (47). A graded and independent association 
of waist-to-hip ratio and body mass index with carotid IMT was found in a cross-
sectional study in middle-aged women (48). There are also conflicting results regarding 
the independent association of body mass index (49) or measures of abdominal obesity 
(51,65) with carotid IMT. 
In previous studies, inconsistent results exist which adipose tissue regions confer the 
greatest increase in morbidity and mortality. There is evidence that abdominal adipose 
tissue influences more disease risk than overall adiposity (52,53). Some studies indicate 
that lower body adiposity, which is predominant in most women, may be in fact 
protective against some disease, such as type 2 diabetes and CVD, rather than being 
harmful (55-57). In postmenopausal women, trunk fat was a strong independent 
predictor of insulin resistance and dyslipidemia, whereas leg fat had protective effects 
against metabolic dysfunction (274). In a cross-sectional study in 4000 men, hip 
circumference was inversely associated with metabolic risk factors (275).  
The different associations of the measures of fat distribution on CVD risk may be 
due to regional variations in the lipolytic activity of human adipose tissue. In the 
visceral region, the rate of lipolysis is high and fat is also more resistant to the metabolic 
effects of insulin compared with peripheral fat cells (see 2.2.1 and 2.2.2). The 
association of visceral fat with inflammation (see 2.2.7) and impaired endothelial 
function (276) support findings that visceral fat is an important risk factor for early 
atherosclerosis. A lesser sensitivity to lipolytic stimulation may explain the greater 
tendency for women to accumulate fat in lower body regions (277). Adipose tissue in 
this region is more likely to take up free fatty acids from the circulation and store them, 
thereby protecting other organs such as liver and skeletal muscle from high free fatty 
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acids (278). Moreover, the favorable metabolic effect of large hip circumference may be 
due to increased gluteal muscle mass and a high lipoprotein lipase activity (279). In 
conclusion, accumulation of fat in the visceral area may increase the risk of metabolic 
and vascular disease more than the amount of total fat. 
6.3.4 Metabolic syndrome and carotid atherosclerosis 
Evidence of the association of metabolic syndrome with carotid IMT is derived mainly 
from cross-sectional studies, of which only a few are population-based (Table 5). Data 
are mainly from middle-aged individuals or have a wide age-range. The present study 
shows that incident metabolic syndrome and an increasing number of metabolic risk 
factors predict the progression of carotid IMT during 12 years in elderly women. The 
mean increase in the carotid IMT was two times greater in those who developed the 
metabolic syndrome than in those who did not. Incident metabolic syndrome was a 
stronger predictor for the progression of carotid IMT than the individual components of 
the syndrome. Of the components, waist circumference and triglycerides contributed 
most to the association between the metabolic syndrome and the change in carotid IMT. 
The present results support the findings of population-based follow-up studies which 
report a direct relationship of the metabolic syndrome (215) or metabolic risk factors 
(204) with carotid IMT or the risk of CVD (258). An important finding is that incident 
metabolic syndrome was associated with the progression of carotid IMT even after 
controlling for Framingham risk score, an international risk assessment tool for 
estimating 10-year risk of developing CHD. This observation suggests that incident 
metabolic syndrome provides additional information for the progression of preclinical 
atherosclerosis beyond conventional risk factors, and thereby improves the prediction of 
clinical CVD. 
The progression rate of carotid IMT in the elderly women in the present study was 
comparable to that recently reported in men 10 years younger from the same area in 
Finland (232). In women, the progression of atherosclerosis increases clearly after 
menopause (280), and CVD is the primary cause of death in women (281,282). The 
prevalence of stroke increases with age in both genders, but women have been reported 
to have a two times higher lifetime risk of dying of stroke than men (283). Also, women 
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with the metabolic syndrome, even without diabetes, were found to have at least a two-
fold higher risk of ischemic stroke or transient ischemic attack (28). 
In these elderly women, the prevalence of the metabolic syndrome increased from 
13% to 46% during 12 years. While body weight remained the same during the follow-
up, waist circumference increased by 10%. This may reflect an aging-associated 
progressive decrease in skeletal muscle mass and increase and redistribution of body fat 
particularly in the abdominal area, worsening of insulin resistance and hormonal 
alterations, all of which are important in the development of the metabolic syndrome. In 
addition to metabolic syndrome, abdominal obesity has been found to predict 
atherosclerosis and clinical cardiovascular events (45-47). In the present study, women 
with incident metabolic syndrome had a higher waist circumference and body mass 
index at baseline than those who did not develop the metabolic syndrome. These 
findings suggest that abdominal obesity is of major importance in the development of 
the metabolic syndrome and also partly explained the association between incident 
metabolic syndrome and the progression of carotid IMT. 
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6.4 Conclusions and future perspective 
Cardiorespiratory fitness and hsCRP may be valuable additions to the definition of the 
metabolic syndrome (Figure 16). The metabolic syndrome in and of itself may improve 
the prediction of preclinical atherosclerosis. When used in conjunction with other 
metabolic and cardiovascular risk factors, low cardiorespiratory fitness and elevated 
hsCRP may have additional predictive power in identifying individuals with multiple, 
often only mildly elevated cardiovascular risk factors, who are at increased risk of 
developing chronic and progressive diseases and who may benefit from lifestyle therapy 
targeting exercise and weight management.  
 
The increasing number of aging individuals in the future will bring along different 
demands to the health care system. Maintaining independent and active living as long as 
possible is a crucial factor for quality of life in aging. The present thesis expands the 
knowledge of the predictors and consequences of the metabolic syndrome in the older 
population. The study also included elderly women, a part of the population that has 
been historically underrepresented in epidemiological studies. These findings emphasize 
the importance of ongoing efforts to identify and treat the metabolic syndrome as early 
as possible to prevent atherosclerotic disease, even in the older population.
 
Further long-term population studies in elderly men and women are needed to clarify 
key factors to be included in the definition of the metabolic syndrome, the relative 
importance of the different components of the metabolic syndrome and the 
combinations of risk factors that are most useful in predicting disease outcomes. 
Randomized controlled clinical trials are needed to find out the dose-dependent effects 
of exercise training and diet on suppression of inflammation and prevention of the 
metabolic syndrome, type 2 diabetes and CVD in population-based samples, including 
older individuals. After finalizing the present thesis I will focus on these issues in the 
ongoing randomized controlled physical exercise and diet intervention study in older 
men and women that forms part of this thesis. 
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Figure 16. Updated view of predictors, components and consequences of the metabolic 
syndrome based on the present thesis. 
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